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 In this work, functional studies of CD157 were carried out using 
adenovirus-mediated infection.  
 Firstly, recombinant viruses containing the inserts CD157 and mutant 
CD157 (mCD157) were constructed. mCD157 was developed by mutating wild 
type CD157 at two sites: Arg103 to Cys103, and Arg184 to Cys184. Previous results 
from our lab showed that such mutations increased the cyclase activity of CD157. 
For expression of CD157 and mCD157, COS-7 cells were co-infected with the 
recombinant virus together with the regulatory tet-off virus. Optimal multiplicity 
of infection (MOI) was found to be 10. Over expression of CD157or mCD157 
was achieved in the absence of tetracycline (tet), while expression was totally 
switched off at a tet concentration of 0.01 µg/ml. Intermediate expression of 
CD157 was observed when tet concentrations used was between 0 to 0.01 µg/ml. 
The Adeno-X Tet-off expression system was hence established in COS-7 cells.  
 Using adenovirus infection, over expression of CD157 and mCD157 in 
COS-7 cells was found to induce phosphorylation of a p130 protein in the absence 
of a CD157 ligand. The cyclase activity of CD157 was probably not involved in 
the induction of signal transduction by CD157 as no significant difference in the 
tyrosine phosphorylation levels of p130 between cells overexpressing CD157 or 
mCD157 was observed, even though mCD157 was previously found to have a 
higher cyclase activity. This p130 protein was found to be focal adhesion kinase 
(FAK) and was phosphorylated on Tyr397 and Tyr861.  
  2
 Lastly, a phosphoproteomics approach was used to study any differences 
in the phosphorylation levels of proteins isolated from cells undergoing different 
treatments: serum-starved cells infected with CD157 virus, serum-starved cells 
infected with β-gal virus and uninfected cells that were serum-starved or 
supplemented with serum. Preliminary results showed that overexpression of 
CD157 indeed resulted in differential phosphorylation of the proteome of COS-7 
cells. Of the differentially phosphorylated proteins, two proteins were identified. 
Phosphorylation of a human HSPCB homologue protein was downregulated in 
cells over-expressing CD157 as compared to the rest of the cells that had 
undergone other treatments. The phosphorylation of another protein, a human 
HSP27 homologue was found to be upregulated in all cells that were infected with 
adenovirus, either with CD157 recombinant virus or β-gal control virus. The 
remaining of the differentially phosphorylated proteins in the different treatments 





















1. 1 Background of CD157 
 
1.1.1  Discovery of CD157 
 It was first found that bone marrow (BM) stromal cell lines derived from 
rheumatoid arthritis (RA) patients have enhanced ability to support B cell growth 
as compared to cell lines derived from normal donors (Kaisho et al, 1992). To 
identify these unknown B-cell growth supporting surface molecules, Kaisho et al 
(1994) prepared monoclonal antibodies (mAbs), RF3 and SG2, against these RA-
derived BM stromal cell lines. They then successfully cloned a novel surface 
molecule designated as BM stromal cell antigen 1 (BST-1). The deduced amino 
acid sequence of BST-1 exhibited 33% identity with human lymphocyte antigen 
CD38, and 26% with Aplysia ADP-ribosyl cyclase (Jackson and Bell, 1990; States 
et al, 1992; Kaisho et al, 1994). Subsequently, Ito et al (1994) and Furuya et al 
(1995) reported the cloning of mouse and rat BST-1 respectively. Murine BST-1 
shows 71% while rat BST-1 shows 72% homology of amino acid sequence with 
human BST-1. 
 Interestingly, sequencing of murine BST-1 by Ito et al (1994) revealed 
that it is the same protein as BP-3 that was previously cloned by Dong and co-
workers (1994). In fact, as early as 1985, Todd et al raised a mAb against an 
unknown antigen, designated Mo5, by immunising mouse with human leukemic 
cells from an acute monocytic leukemia patient. Later in 1997 in the 6th Human 
Leukocyte Differentiation Antigen (HLDA) Workshop, this seemingly unrelated 
anti-Mo5 antibody was found to recognise human BST-1. Finally, in the same 
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workshop, human Mo5, human BST-1 and murine Bp-3 were clustered as CD157 
(Ishihara et al, 1997).  
 
1.1.2   CD157 gene organisation 
 CD157 gene is assigned to chromosome 4p15 (Ishihara et al, 1997), 
identical to that of its human paralogue, CD38 (Nakagawara et al, 1995). The 
genomic structures of CD157, CD38 and Aplysia california ADP-ribosyl cyclase 
have revealed that CD157 and CD38 evolved from a common ancestor by gene 
duplication (States et al, 1992; Ferrero and Malavasi, 1997; Nata et al, 1997). 
Pulse-field gel electrophoresis (PGFE) analysis carried out by Ferrero and co-
workers (1999) led them to suggest that CD157 and CD38 are contiguous in the 
human genome in the 5’ – 3’ order CD157 → CD38. 
 The CD157 gene consists of nine exons and eight introns. The length of 
the exons are 391, 127, 146, 73, 87, 83, 61 and 432 base-pairs (bp) respectively 
(Muroka et al, 1996). Exon 1 encodes the 5’UTR, the signal peptide and the N-
terminal 32 amino acids while exons 2-8 encode the remainder of the extra-
cellular region. Exon 9 encodes a short hydrophobic peptide which signals the 
attachment of a glycosylphosphatidyl inositol (GPI) anchor, along with the 3’UTR 
(Ferrero et al, 2002). When compared with CD38, the gene organisation was 
found to be very similar. Exons 2-8 of CD157 are identical to that of CD38: the 
introns have almost the same length and the exons code for the same amino acid 
number (Ferrero and Malavasi, 1997). High similarity in gene organisation was 
also observed between the Aplysia ADP-ribosyl cyclase gene (Nata et al, 1995) 
and that of CD157 and CD38. Exon 3 and 4 of CD157 contained regions 
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corresponding to exon 4 of ADP-ribosyl cyclase, indicating that in the course of 
evolution, an intron insertion has occurred. This insertion probably occurred in the 
precursor of CD38 and CD157 before the gene duplication event that gave rise to 
these two paralogs. CD157 and CD38 exon 5 is one amino acid smaller than exon 
5 of the cyclase gene while their exon 6 is one amino acid longer than that of the 
cyclase gene. Exons 7 of all three genes encoded the same number of amino acid 
residues (Muroka et al, 1996). In addition, deduced amino acid sequence of 
human CD157, human CD38 and Aplysia ADP-ribosyl cyclase showed that the 
positions of ten cysteine residues in these proteins are completely conserved 
suggesting that their tertiary structures are similar (States et al, 1992; Ferrero and 
Malavasi, 1997; Nata et al, 1997).  
 
1.1.3 The regulatory region of the CD157 gene 
The 5’ flanking region of the human CD157 gene has consensus 
sequences for interferon responsive elements such as interferon γ response 
element (γ-IREs) and interferon stimulated response element (ISRE)-like 
elements, potential binding sites for nuclear transcription factors such as E2A, 
adaptor protein 2 and 3 (AP2 and AP3), polyomavirus enhancer A-binding protein 
3 (PEA3), CCAAT/enhancer binding protein (C/EBP), cAMP response element-
binding protein (CREB), specificity protein (SP1) and p53, and consensus motifs 
for cytokine-responsive factors such as nuclear factor for IL-6 gene (NF-IL-6) and 
Nuclear Factor κB (NF-κB) (Muraoka et al, 1996). The human CD157 gene lacks 
a TATA box, suggesting the possibility having multiple start sites (Muraoka et al, 
1996). Similarly, murine CD157 gene lacks a TATA box and also contains 
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consensus binding sites for transcriptional factors, such as PU.1, LyF-1/Ikaros, 
E2A, TCF-1 which regulate gene expression in lymphoid and myeloid cells (Dong 
et al, 1996). Consensus motifs for cytokine-responsive factors NF-IL-6/C-EBP, 
H-APR-1/APRF, and AP-1 are also present in the flanking regions (Dong et al, 
1996). All these elements suggest that the CD157 gene may be upregulated by 
events such as DNA damage, inflammation and infection, while NF-IL6 and NF-
κB binding sites may explain the increased expression of CD157 molecule in 
rheumatoid arthritis (RA) patients.  
Anani and co-workers (2001) found that both all-trans retinoic acid 
(ATRA) and α1,25-dihydroxyvitamin D3 (VD3) were able to upregulate the 
expression of CD38 and CD157 in HL60 cells. Surprisingly, expression patterns 
of CD38 and CD157 after ATRA exposure were similar, though the ATRA-
induced overexpression of CD157 antigen was lower and belated in comparison 
with CD38. To date, retinoic acid-inducible element (RARE) has not been found 
in the 5’-flanking region of CD157 and this led them to suggest that the RARE 
described in intron 1 of CD38 (Kishimoto et al, 1998) might be involved in the 
transactivation of CD157. RARE, technically known as a DR5 repeat (sequence = 
TGACCCgaaagTGCCCC) lies at bp 437-453 of intron 1. 
When analogous sequence from the regulatory regions of human CD157 
was superimposed with CD38, very little sequence conservation, with the 
exception of two short regions, were maintained (Ferrero et al, 2002). The finding 
of little homology between the paralogs in their regulatory regions probably 
explains the reason for duplication: a second copy of a gene can acquire a 
different temporal and spatial pattern of expression (Li and Noll, 1994). In fact, 
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when expression of CD38 and CD157 were compared in human hematopoietic 
cells, one sees that expression of one often means the inactivation of the other 
(Ferrero et al, 2002). 
  
1.1.4    Molecular characterisation of CD157 
The human CD157 cDNA encodes a protein consisting of 318 amino 
acid residues. It also has a putative signal peptide spanning from residue 1 to 28 
which is abundant in hydrophobic amino acids. This suggests that the mature 
protein probably consists of 290 amino acids (Kaisho et al, 1994). However 
Hirata et al (1994) reported that a soluble form of CD157 (sCD157) precursor 
peptide is cleaved between Ala32 and Arg33. N-terminal sequence analysis also 
showed that this form of CD157 contained only 286 amino acids. In addition to 
the signal peptide, CD157 contains a short C-terminal hydrophobic region that 
anchors it to the outer surface of the plasma membrane via a GPI anchor (Kaisho 
et al, 1994, Lee et al, 1996). This anchor could be broken by treatment with 
phosphatidylinositol-specific phospholipase C (PI-PLC) (Kaisho et al, 1994). 
Analysis using anti-Mo5 mAb showed the CD157 is synthesized as a 
41kDa precursor which is converted to the mature glycoprotein within 1-4hr in 
both U937 and polymorphonuclear (PMN) cells when the signal sequence at its 
COOH-terminus is cleaved off in the endoplasmic reticulum and replaced by the 
GPI anchor (Goldstein and Todd, 1993). The glycosylated human CD157 protein 
is a single-chain of 42-45kDa (Kaisho et al, 1994; Lee et al, 1996) while the 
deglycosylated form upon N-glycanase treatment is 31kDa (Hirata et al, 1994). 
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This suggests the presence of post-translational modifications which account for 
approximately 12% of the total mass of the protein (Hirata et al, 1994).  
CD157 contains four N-linked glycosylation sites, Asn66, Asn95, Asn148, 
Asn192, with Asn-X-Ser/Thr recognition signals, in the extracellular region 
(Yamamoto-Katayama et al, 2001). Treatment with glycosylation inhibitor, 
tunicamycin, reduced the amount of sCD157 released in the culture medium 
indicating glycosylation is essential for the secretion of the molecule (Yamamoto-
Katayama et al, 2001). Site-directed mutagenesis of each of the four N-linked 
glycosylation sites has shown that N-glycosylation facilitated the folding of the 
nascent polypeptide chain into a conformation that allows for intracellular 
transport and functional activities (Yamamoto-Katayama et al, 2001). 
Carbohydrates attached to Asn66, Asn148 or Asn192 are necessary for secretion. The 
glycosylated moieties attached to Asn148 or Asn192 are needed for the ADP-ribosyl 
cyclase activity while the glycosylation site of Asn192 may be important for the 
hydrolase activity. In fact, CD157 shares the glycosylation site of Asn192 with 
CD38 (Yamamoto-Katayama et al, 2001). Hence, each glycosylation site of 
CD157 may have distinct roles. 
 
1.1.5 Crystal structure of CD157 
 Yamamoto-Katayama et al (2002) have carried out extensive 
crystallographic studies on human CD157, both in the ligand-free state and when 
complexed with substrate analogues such as nicotinamide, nioctinamide 
mononucleotide (NMN), adenosine 5’-O-(3-thiotriphosphate) (ATPγS), 
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nicotinamide 1,N6-etheno-adenine dinucleotide phosphate (ethenoNADP), and 
nicotinamide 1,N6-etheno-adenine dinucleotide (ethenoNAD). In agreement with 
the biochemical findings of Sato and co-workers (1999b), Yamamoto-Katayama 
and co-workers (2002) found that CD157 forms a homodimer where each domain 
separately interacts with its symmetrical mate (Figure 1.1a). The dimer interface 
involves both polar and hydrophobic interactions between α-helices such as α1-
α2, α4-α4, α9-α9 and α4-α9. In fact, the overall dimer structure of CD157 
resembles that of Aplysia cyclase (Prasad et al, 1996), although the relative 
orientation of the N domain to the C domain is significantly different between 
these two proteins, with inclination smaller by about 15o in CD157 compared to 
that of Aplysia cyclase (Figure 1.1b). On the contrary, the secondary structure 
elements are well imposed between the two dimeric proteins. The dimensions of 
the dimer interface are almost equivalent between the two enzymes except that it 
is more hydrophobic in CD157 (Yamamoto-Katayama et al, 2002). 
 Each subunit of CD157 dimer is divided into two domains, the N 
domain, which is constituted by residues 2-68 and 98-150, and the C domain, 
which is constituted by residues 69-97 and 151-251. A hinge region of three 
peptide chains connects both the N and the C domains (Figure 1.1a) (Yamamoto-
Katayama et al, 2002). The internal architecture of each domain is identical with 
Aplysia cyclase (Prasad et al, 1996). All ten cysteine residues, which are 
conserved among the cyclase family, form disulphide bonds: Cys19-Cys35, 
Cys51-Cys131, Cys112-Cys125, Cys206-Cys227 and Cys239-Cys248 
(Yamamoto-Katayama et al, 2002). Each subunit also contains a substrate- 
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Figure 1.1. Crystal structure of CD157 complexed with ethenoNAD 
(Yamamoto-Katayama et al, 2002). (a) Ribbon representation of the CD157 
dimer structure and stick models of ethenoADPR and nicotinamide, which are 
metabolites of ethenoNAD. The compounds are coloured according to their 
identities: carbon, oxygen, nitrogen and phosphorus are depicted in dark blue, red, 
blue and yellow respectively. (b) Structural comparison of CD157 (red) and 
Aplysia cyclase (blue). The two structures are superimposed so as to make the best 
fits on the Cα atoms of the secondary structure in the C domain. 
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binding cleft formed by the N and C domains. This large cleft, surrounded by α4, 
α5, α6, α7, and β1, is covered mainly by hydrophobic and acidic residues and its 
overall dimensions are approximately 15 Å by 12 Å by 10 Å, which are the same 
as those of Aplysia cyclase (Yamamoto-Katayama et al, 2002). 
 
1.1.6 Cellular expression and tissue distribution of CD157 
 Part of the information available about murine and human CD157 was 
gathered before the molecules were clustered. Analysis of the distribution of 
human CD157 was initiated earlier and independently from the murine 
counterpart with anti-CD157 mAbs (RF3, BEC7 and Mo5). It has been revealed 
that human CD157 is expressed on BM stromal cell lines, synovial cell lines, 
HUVEC, follicular dendritic cell lines, myelomonocytic cells lines, majority of 
myeloperoxidase–positive myeloid precursors in the BM, granulocytes 
(eosinophils, basophils, neutrophils), mast cells, monocytes and in vitro 
differentiated macrophages (Todd, 1995; Ishihara et al, 1997). Leukemic cells 
expressing CD157 were also found in more than half of the cases with acute 
monocytic leukemia and acute granulocytic leukemia but not in the cases with 
lymphocytic leukemia (Todd et al, 1985). 
Expression of CD157 was also modulated by the different treatments 
carried out on leukocytes. Calcium ionophore upregulates CD157 expression on 
neutrophils while divalent anti-Mo5-mAb downregulates its expression (Todd et 
al, 1985); FMLP upregulates CD157 on neutrophils and basophils but not on 
monocytes; PAF upregulates CD157 expression on eosinophils (Todd, 1995). 
Tumour necrosis factor-α (TNF-α) upregulates while granulocyte/macrophage 
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colony-stimulating factor (GM-CSF) downregulates CD157 expression on U937 
(Todd, 1995) In nurse-like cells established from synovium or BM of RA patients, 
IFN-γ upregulates CD157 (Shimaoka et al, 1998). 
In mouse, the earliest observations concerning tissue distribution were 
made using the BP3 mAb (McNagny et al, 1988). CD157 is transiently expressed 
by early progenitors of murine B and T lymphocytes and was detected on fetal 
liver B progenitors 16-17 days into gestation but absent in pre-pro B cells in BM, 
though the molecule is detected on the majority of pro-B cell fractions (Ishihara et 
al, 1996). This suggests that CD157 becomes expressed with the DJ 
rearrangement of immunoglobulin (Ig) heavy chain genes (Ortolan et al, 2002). 
The CD157+ subpopulation of the B cells in BM and peripheral tissues displayed 
an immature phenotype of high level of surface IgM and low level of IgD while 
their mature counterparts do not express CD157 (McNagny et al, 1988; Ishihara et 
al, 1996). CD157 on murine T cells also shows a stage-restricted expression 
pattern (Vicari et al, 1996). CD157 was detected on fetal thymus 14 days into 
gestation and reach maximum expression on day 15 and 16, followed by a gradual 
decrease until birth (Vicari et al, 1996). CD157 was expressed in the CD44-
CD25+ and CD44-CD25+ fractions of pro-T cells in both fetal and adult 
thymocytes, suggesting that CD157 may have a role in TCR gene arrangement in 
T progenitors (Vicari et al, 1996). 
Using immunohistochemical analysis, murine CD157 was found to be 
present on the brush borders of the intestinal epithelial cells covering most of the 
villi and within the collecting tubules of the kidney (McNagny et al, 1991). It is 
also expressed on a subset of reticular cells in lymph nodes, Peyer’s patches and 
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the splenic white pulp, but not on reticular cells located in the thymus, BM or 
splenic red pulp (McNagny et al, 1991). 
Seki et al, (2001) established a monoclonal antibody that recognised 
both mouse and rat CD157. They found striking differences in both the level and 
the stage of CD157 expression in the primary lymphoid organs between mouse 
and rat. Rat CD157 is expressed by more than 90% of thymocytes while 
expression in mouse is not more than 13%. In addition, rat CD 157 expression is 
expressed at a lower percentage when compared to the mouse. Finally, the 
majority of rat CD157+ B cells appears at the pre-B (IgM-) stage while that in 
mouse is maintained up to the immature B (IgM+) stage. Northern blot analysis 
revealed that both human and mouse CD157 genes are expressed in the lung and 
kidney, but not in the brain (Dong et al, 1994; Itoh et al, 1994; Kaisho et al, 
1994). From the tissues of each species examined, human CD157 is expressed in 
the placenta and liver, while murine CD157 is expressed in the BM, spleen, 
thymus, intestine and heart, but not in the liver (McNagny et al, 1991; Dong et al, 
1994). Such a pattern of expression suggests the multiple functions of CD157 in 
organs other than hematopoietic systems (Ishihara and Hirano, 2000). It would be 
of great interest for further investigation given the great similarities of the 
mammalian physiological systems but apparent dissimilarities of the distribution 
pattern among human, mouse and rat. 
A summary of the expression of CD157 is shown in Table 1.1. 
 
1.1.7 CD157 functions as an enzyme 
From the structural homologies of CD157 with CD38 and Aplysia ADP-
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Tissue Cellular Distribution Putative Function 




Nurse like cells 
 
B cell maturation 
Myeloid maturation 
Pre-B cell differentiation 






Liver Fetal B progenitors (mouse) 
 
B cell maturation 





Lymph nodes Follicular reticular cells 
 
Homing (?) 
Thymus T progenitors (mouse/rat) 
 
T cell maturation 
Vessel Enthothelial cells 
 
Leukocyte homing (?) 




Uterus Mast cells 
 
 
Kidney Collecting Tubules 
 
 








Pancreas α and β (mouse) 
 
 
Insulin and glucagons 
secretion (?) 
Joint Synovial cells 
Nurse-like cells 
 
B cells activation (RA) 





Table 1.1. Putative functions potentially attributable to the CD157 molecule 
in different environments and organs (Ortolan et al, 2002).  
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ribosyl cyclase, it was expected that CD157 would have similar enzymatic 
activities as these proteins (Dong et al, 1994; Itoh et al, 1994; Kaisho et al, 1994; 
Dong et al, 1996). Recombinant human sCD157 incubated with NAD produces 
cADPR and ADPR, indicating that CD157 has both ADP-ribosyl cyclase and 
cADPR hydrolase activities (Hirata et al, 1994):  
 
NAD+                          cyclic ADP-ribose (cADPR) + nicotinamide 
 
cADPR + H2O                           ADP-ribose (ADPR) 
 
CD38 also have both cyclase and hydrolase activities and its catalytic 
efficiency is several hundred folds higher than that of CD157 (Hussain et al, 
1998). As shown by Hirata and co-workers (1994), the ADP-ribosyl cyclase 
activity of sCD157 requires metal ions and is pH-dependent. Presence of Zn2+ and 
Mn2+ increases the cyclase and hydrolase activities of both CD157 and CD38 
(Zocchi et al, 1993). However, Cu2+ showed an inhibitory effect on the cyclase 
and hydrolase activities of CD157 but an enhancing effect on the cyclase activity 
of CD38 (Zocchi et al, 1993; Hirata et al, 1994 ). The optimal pH for the activity 
of CD157 is in the range of 4-6.5 (Hirata et al, 1994). This relatively weak cyclase 
activity of CD157 in acidic pH suggests that CD157 may not be enzymatically 
active in physiological situation (Hussain et al, 1998). 
Sato et al (1999a) developed a peptide inhibitor specific (SNP-1) to the 
enzymatic activities of CD157 by screening a 15-mer random peptide phage 




of peptide SNP-1 inhibited sCD157 cyclase activity in an uncompetitive manner. 
SNP-1 also inhibited cADPR hydrolase activity, which suggests that the SNP-1 
binding site of CD157 is a critical domain for maintaining the conformation for 
both enzymatic activities and binding site of substrates. Since SNP-1 only affects 
CD157 and not CD38, this makes it a specific inhibitor of CD157 on cells 
expressing both CD157 and CD38. 
Based on the structural views of CD157 when complexed with different 
substrate analogues, Yamamoto-Katayama and co-workers (2002) proposed a 
reaction mechanism for CD157 intramolecular cyclase and hydrolase activity. In 
their scheme, both enzymatic reactions take place via a single oxo-carbenium ion 
intermediate generated by the cleavage of the N-glycosidic bond in NAD through 
an SN1-type reaction mechanism. The catalytic cleft of CD157 functions to 
stabilise a transition state for the formation of the cationic intermediate. After the 
generation of the intermediate, the reaction proceeds with cyclisation pathway 
(Path I) or the hydrolysis pathway (Path II) (Figure 1.2). In the cyclisation 
pathway, there is a nucleophilic attack of the adenine N1 atom of NAD against the 
oxo-carbenium intermediate. After the cleavage of the N-glycosidic bond, the 
adenine base replaces the released nicotinamide in the catalytic cleft by an 
aromatic-aromatic interaction with the side-chain of Trp140. The indole side- 
chain of Trp140 appears important as it determines the relative position of the 
adenine base to the ribose so that the cADPR can be formed. In the hydrolysis 
pathway, water molecules around the catalytic cleft attack the intermediate to 
produce ADP-ribose.  
The ability of CD38 and CD157 to synthesize cADPR strongly suggests
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Figure 1.2. Proposed mechanisms for ADP-ribosyl cyclase and NAD 
glycohydrolase reactions of CD157 (Yamamoto-Katayama et al, 2002). (a) 
Substrate recognition. The amino acid residues in the catalytic cleft stabilize a 
transition state for the cleavage of the N-glycosidic bond. After the nicotinamide 
is released (1), the adenine base occupies the nicotinamide-binding site (2). (b) 
Stabilisation of an oxo-carbenium ion intermediate. The intermediate proceeds 
according to two competing pathways: Path I, the cyclisation pathway and Path II, 
the hydrolysation pathway. 
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their involvement in cytosolic Ca2+ current. cADPR was first discovered as an 
inducer of intracellular Ca2+ in sea urchin eggs (Clapper et al, 1987). The enzyme 
responsible for the production of cADPR was later identified and named as ADP-
ribosyl cyclase (Lee et al, 1989). It was indeed later found that cADPR is a potent 
Ca2+ mobilising agent from ryanodine-sensitive, inositol 1,4,5-triphosphate (IP3)-
independent intracellular stores (Lee et al, 1994). These stores are involved in 
biological functions such as glucose-induced insulin release in the endocrine 
pancreas (Takasawa et al, 1993), cardiac (Meszaros et al, 1993) and intestinal 
longitudinal muscle contraction (Kuemmerle and Makhlouf, 1995) and 
lymphocyte proliferation (Guse et al, 1999). 
 An apparent contradiction observed here is that while the catalytic 
activities of both CD38 and CD157 are localised at the outer cell surface, the 
substrate, NAD+, is found prevalently inside the cell. One hypothesis proposed 
that CD38 is induced to internalise by an antibody (Funaro et al, 1998) or by the 
substate (Zocchi et al, 1996; Chidambaram and Chang, 1999) so that enzymatic 
activity of CD38 could be shifted into the cytoplasmic compartment. Another 
alternative is that the members of the family are not only surface-bound, but are 
also present within the cells. In fact, enzymatically active CD38 have been 
reported inside the cells, either in the cytoplasm or in the nucleus (Khoo and 
Chang, 1999; Sun et al, 1999; Khoo et al, 2000). On the other hand, if CD38 
which are expressed on the outer surface of the cell membrane are involved in 
Ca2+ calcium signalling, then the question remains as to how cADPR synthesized 
by the cyclase is transported into the cell. One speculation is that CD38 acts as a 
transporter by forming dimer or even tetramer on cell membrane to create a 
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channel for the entry of cADPR (Bruzzone et al, 1998; Franco et. al., 1998). 
Although there is little information about CD157 on this, the homology suggests 
the transportation function of CD157 may be similar to that of CD38. 
 
1.1.8 CD157 functions as a receptor 
CD157 is able to act as a receptor to generate signals. The functions of 
CD157 as a receptor and the signals transduced have been analysed using mAbs 
mimicking natural ligand(s). Okuyama et al (1996) first demonstrated the receptor 
function of CD157 in CHO cells. They produced a stable transformant 
overexpressing CD157 on the surface. Five mins after cross-linking the surface 
CD157 molecules with a polyclonal anti-human CD157 antibody, they observed 
tyrosine phosphorylation of a 130kDa protein and dephosphorylation of a 100kDa 
protein. In addition, the growth of CHO-CD157 stable transformant was partly 
inhibited as judged by longer doubling time (Okuyama et al, 1996). CD157-
mediated tyrosine phosphorylation of the 130kDa protein was also observed in 
U937 and THP-1 cell lines (Okuyama et al, 1996). Previous work from our lab 
has also shown that recombinant CD157 expressed in COS-7 and MCA-102 and 
CD157 on monocytes, differentiated from HL-60 (mHL60) cells by VD3 
treatment, also induced mediated the tyrosine phosphorylation of 130-kDa protein 
(Hussain and Chang, 1999; Liang et al, 2001). The CD157-mediated p130 
tyrosine phosphorylation was ligand-dependent in mHL60 cells but ligand-
independent in MCA/CD157 cells (Hussain and Chang, 1999). The tyrosine-
phosphorylated p130 from MCA/CD157 stable transformants were later identified 
as the focal adhesion kinase (FAK or pp125FAK) (Liang et al, 2001). However, 
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Liang et al (2001) reported that p130 does not correspond to FAK in other cell 
lines, indicating cell type specificity of the CD157-mediated signalling 
mechanism.  
A point of interest of CD157 as a receptor is, with its being GPI-
anchored without any appropriate cytoplasmic structures, how it is able to 
transduce signals. There should be partner molecules for CD157. CD157-
associated molecules, its substrates for tyrosine phosphorylation, and the relation 
between tyrosine phosphorylation and the elicited cellular functions should be 
examined (Ishihara and Hirano, 2000). However, to date, no partner proteins have 
been described (Pfeffereorn and Sylvester, 2001). Alternatively, CD157 might use 
its GPI linkage for signaling. A growing number of surface receptors have been 
identified that use GPI linkers to induce signal transduction as summarised by 
Martin (1998). Evidences have suggested that many GPI-anchored proteins would 
relocate to caveolae after cross-linking with antibodies or ligands (Schnitzer et al, 
1995) while others showed that they natively exist in caveolae constitutively 
(Stahl and Mueller, 1995; Lupu et al, 1997). The clustering of GPI-anchored 
molecules could generate threshold levels of activation signals especially by 
protein tyrosine kinases (PTKs) at the cytoplasmic side and initiate 
autophosphorylation and activation of PTKs, followed by substrates 
phosphorylation and triggering of signaling cascades (Rodgers et al, 1994; 
Zlatkine et al, 1997). Recently, Liang et al (2002) showed that CD157 colocalised 
with caveolae. They proposed that an overexpression of CD157 led to its 
dimerisation and relocalisation to caveolae to initiate the signalling process. 
Finally, biological significance of the antibody-induced signal transduction will 
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also be clarified by the identification of ligands. Existence of a ligand for CD157 
is suggested by the binding of biotinylated soluble CD157 to human B-cell lines 
(Ishihara and Hirano, 2000). 
 
1.1.9 CD157 as a myeloid antigen 
Results obtained from the 5th HLDA Workshop attributed several 
functional roles to CD157 molecule in myeloid cells. Mo5 mAb was found to 
inhibit transepithelial migration of neutrophils, induce generation of superoxide in 
U937 cells and suppress phagocytosis of bacteria by neutrophils (Todd, 1995). 
CD157 expression is maturation-dependent on human myeloid cell lines as 
indicated by the stage-restricted detection in mature cells but not on their 
precursors (Goldstein and Todd, 1993). This suggests that CD157 plays functional 
role(s) in myeloid differentiation.  
Expression and regulation of CD157 was evaluated in HL60 cells in our 
laboratory. The results showed that cells were differentiated into monocytes when 
treated with VD3, TNF-α and arabinosylcytosine (ara-C), into 
granulocytes/neutrophils when treated with ATRA or dimethylsulfoxide (DMSO), 
and into macrophages when treated with phorpho-12-myristate-13-acetate (PMA) 
(Hussain et al, 2000). The expression of CD157 was irreversibly upregulated in a 
concentration- and time-dependent manner by all these inducers (Hussain et al, 
2000; Anani et al, 2001). VD3-induced upregulation of CD157 involved a cAMP-
dependent mechanism while PMA induced its downregulation (Hussain et al, 
2000). Using other differentiation agents, Anai et al (2001) found that granulocyte 
colony-stimulating factor (G-CSF), GM-CSF and 12-O-tetradeconoylphorbol-13-
  23
acetate (TPA) have no effect on the expression of CD157. Results have also 
shown that CD157 is upregulated after exposure to As2O3 and VD3 in the more 
mature cell lines (Deaglio et al, 2001). 
 
1.1.10 CD157 as an immunoregulatory molecule 
In the murine in vitro system, evidences from experiments using anti-
CD157 mAbs showed the synergistic effects on anti-CD3-induced growth of pre-
T cells and facilitation of the development of αβ TCR+T cells in fetal thymic 
organ cultures (Vicari et al, 1996). Murine models also showed that the 
expression of B cell progenitors parallels the DJ rearrangement of the Ig heavy 
chain gene (Ishihara et al, 1996). These results suggest that CD157 has a role in 
lymphopoiesis.  
Surprisingly, in vivo studies of the humoral immune responses of CD157 
knockout (KO) mice showed otherwise. The major populations of 
lymphohematopoietic cells in adult CD157 KO mice were normal except for the 
delayed appearance of peritoneal B-1 cells and increase of CD38low/- B 
lymphocytes in the BM and spleen (Ishihara and Hirano, 2000). Another 
unexpected observation is that without stimulation, serum Ig levels in CD157 KO 
mice were normal. However, when CD157 KO mice were stimulated with TI-2 
and TNP–Ficoll antigen, the IgG3 class of immune response was reduced to one-
third that of the control (Ishihara and Hirano, 2000). This specific impairment of 
IgG3 in response to TI-2 antigen suggests that CD157 may be involved in 
supporting B cells undergoing class-switch (Ishihara and Hirano, 2000). In 
addition, oral immunisation with thymus-dependent antigen cholera toxin (CT) 
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lead to a low production of anti-CT antibody of IgA and IgG classes in the faecal 
extract. This was a result of reduced number of antigen-specific antibody-
producing cells in the intestinal lamina propria (Itoh et al, 1998). It is then 
suggested that in the microenvironment of Peyer’s patches, without CD157, the 
precursor B cells of IgA-producing cells might not fully develop and was unable 
to migrate to the lamina propria, or to differentiate to IgA-producing plasma cells 
(Ishihara and Hirano, 2000). Interestingly, in LT α/β-deficient KO mice, from 
which microarray analysis revealed that its expression of CD157 in the spleen is 
greatly reduced, reduction of IgA expression was observed in correlation to the 
deficient CD157 expression (Staudt and Brown, 2000). Immunohistochemical 
analysis also showed that BP-3 antigen expression is greatly reduced in splenic T 
and B zones of TNF and TNF receptor 1 KO mice and was undetected in LT α/β-
deficient KO mice (Ngo et al, 1999). These findings showed that CD157 is 
involved in the regulation of the humoral T-independent immune responses and 
mucosal thymus-dependent responses. 
 
1.1.11 Pathological role of CD157 in rheumatoid arthritis 
CD157 is believed to play a role in RA. RA is a systemic autoimmune 
disease characterised by chronic polyarthritis. Initial pathological changes include 
microvascular injury and proliferation of synovial lining cells with perivascular 
infiltration of mononuclear cells. Inflammatory synovitis persists and in severe 
cases, the joints are damaged. One of the abnormalities in RA is polyclonal B-cell 
activation which leads to hypergammaglobulinemia and production of rheumatoid 
factor (Ishihara and Hirano, 2000). Changes in the BM microenvironment are also 
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thought to be involved in the pathogenesis of RA (Ortolan et al, 2002). Kaisho et 
al (1992) first showed that RA-derived BM stromal cells have the ability to 
support the growth of a pre-B cell line. CD157, which is highly expressed on 
these RA-derived BM stromal and synvovial cell lines, was later shown to be 
partly responsible for this growth supporting capability (Kaisho et al, 1994). In 
addition, through immunohistochemical analysis, CD157 was detected in the 
superficial lining cells of the synovium in 6 out of 10 of severe RA cases (Ishihara 
and Hirano, 2000). 
Nurse-like cells (NLC) lines established from the BM and synovium of 
patients with RA were also found to express CD157 constitutively (Shimaoka et 
al, 1998). These cells were shown to rescue B cells from spontaneous apoptosis 
and promoted the survival of B cells for more than 4 weeks. Addition of sCD157 
further enhanced the survival of B cells while addition of anti-CD157 antibodies 
to the culture medium inhibited the supporting effect (Shimaoka et al, 1998). 
Another typical feature of RA is the presence of high concentrations of 
sCD157 in the sera of RA patients as compared to that of healthy donors. 
Furthermore, patients with severe RA showing joint destruction were found to 
have very much higher concentration of sCD157 than the majority of RA patients. 
It is thus suggested that overexpression of CD157 or high serum sCD157 may 
accelerate the progress of RA (Ishihara and Hirano, 2000). It was also speculated 
that though overexpression of CD157 may help in the survival or growth of 
synovial cells, excess sCD157 may cause modification of the microenvironment 
by accumulating the enzymatic products. In addition, sCD157 may also modify 
  26
CD157-mediated signal transduction in neutrophils, monocytes and macrophages 
and thus maintain their continued activation (Ishihara and Hirano, 2000). 
1.2 Adenovirus–X Tet-off Expression System 
1.2.1 Adenovirus 
1.2.1.1 Biology of adenovirus 
Wild-type adenovirus exists as an icosahedral particle of approximately 
17nm in diameter with a dense core containing the DNA genome (Horwitz, 1990). 
Human adenovirus serotypes 2 (Ad2) and 5 (Ad5) are most extensively studied. 
The double-stranded, linear DNA genome is 36 kilobases (kb), which can be 
manipulated by standard recombinant technology (Doefler and Böshm, 1995).  
The lytic life cycle of the wild-type virions can be divided into early and 
late phases with the early phase being defined as occurring before the onset of 
viral DNA replication while late phase as after the onset of viral DNA replication. 
Genes expressed during the early phase are noncontiguous in the genome which 
includes the E1 regions, E1A and E1B, the E2 regions, E2A and E2B, E3 and E4 
(Figure 1.3). In the late phase, the major late promoter (MLP) is activated and is 
responsible for most of the transcriptional activity. MLP-driven transcripts contain 
multiple open reading frames that are alternatively spliced to give mRNAs 
containing 5’untranslated regions known as the tripartite leader (Horwitz, 1990). 
Late in infection, 20-24% of the total cellular RNA is viral and cell lysis begins to 
occur 48-72 hr after infection. 
The E1 genes are required for viral transformation. E1A appears to be 
required for activation of all other early genes (E1B, E2, E3 and E4). The E1 and 
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E4 regions encode proteins for regulation of viral and cellular genes; the E2 genes 
encode three proteins directly involved in viral DNA replication; and the E3 
region is primarily directed toward modification of the host immune response.The 
viral late genes, L1-L5, are expressed from a common major late promoter and 
encode the structural proteins for packaging viral DNA into infectious particles. 
All viral proteins can be provided in trans. The only elements required in cis are 
the two inverted-terminal repeats (ITRs, 103bp each) that are essential for viral 
DNA replication and a 170-bp packaging region that is required for packaging the 
DNA into virion particles. The packaging region is located at the 194 to 358bp 
near the left ITR (Zhou et al, 2002). 
 
1.2.1.2 Development of the adenovirus vector 
The development of adenovirus as expression vectors has focused on 
crippling the virus by deleting essential genetic regions and complementing the 
missing function(s) in trans using engineered cell lines or viral helper system.  
First-generation adenoviral vectors were made by replacing the E1 
region of the viral genome with the gene of interest (Graham and Prevec, 1991). 
These E1-deleted adenoviral vectors are propagated in E1 complementing 293 
cell-line, which was originally transformed with Ad5 and has the E1 region of the 
adenovirus genome integrated into its cellular DNA (Graham et al, 1977). The E3 
regions in some first-generation vectors were also removed to increase the 
carrying capacity. With the deletion of both E1 and E3 regions, up to a maximum 
insert size of 7kb (Graham and Prevec, 1991) could be introduced. However, in in 
vivo systems, these vectors can elicit immune and inflammatory response (Yang et 
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al, 1994). To overcome the limitations of the first generation vectors, second-
generation adenoviral vectors with deleted E1 and E2 (Gorziglia et al, 1996) or E1 
and E4 were developed (Armentano et al, 1997). These viruses can be propagated 
in cell lines that complement both E1 and E2 (Zhou et al, 1996) or E1 and E4, 
respectively (Brough et al, 1996). 
Another strategy to reduce immunogenicity and improve the safety of 
adenoviral vectors is to delete all viral coding sequences (E1, E2 and E4), so that 
leaky expression of viral proteins is completely eliminated. This type of vector 
depends on a helper virus to provide viral proteins in trans, and hence is called 
helper-dependent adenoviral (HD-Ad) vectors. These vectors are also sometimes 
called gutless or gutted vectors (Conner et al, 2002). They have a much higher 
carrying capacity and had been reported to carry as large as a 30kb insert 
(Kochanek et al, 1996). The inverted terminal repeats and packaging sequences 
are always retained so that it can be packaged into viral particles (Kovesdi et al, 
1997). However, such vectors are more difficult to propagate and purify than 
conventional adenoviral vectors. One solution was to use cre-mediated 
recombination techniques to limit the amount of contamination by helper virus. 
Lieber et al (1996) reported that this strategy allowed them to reduce the helper 
virus to less than 0.5%.  
 
1.2.1.3 Use of adenovirus in vitro and in vivo 
There are several major advantages of using adenoviral vectors. They 
can be produced at high titer (1012-1013 virus particle per ml); are able to infect 
postmitotic and dividing cells as opposed to retroviral vectors, which only infect 
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dividing cells; have the ability to infect a wide variety of cell types; are stable as 
attributed by its double-stranded DNA genome; and can accommodate large insert 
size. In addition, since the adenoviral genome is maintained extra-chromosomally, 
insertion of site-dependent effects of the host genome are minimized. Most 
importantly, safety precedents exist when safety is concerned as adenovirus-based 
vaccines have been used in humans without side effects. This is especially 
important in its application in gene therapy (Kovesdi et al, 1997). 
Use of adenoviral vectors has been widely reported with much success. 
Abundant evidence suggests that the virus efficiently transfers genes to a wide 
range of cell types (Hitt et al, 1997). This property of adenovirus can be 
advantageous for rapid evaluation of the effects of introduced gene in clonal cells. 
Using such a system would also negate the need for stable transfection and 
selection of transfected clones by antibiotic resistance, which is both tedious and 
time-consuming (Becker et. al., 1994). In addition to clonal cell lines, various 
studies also reported the use of adenoviral vectors in primary cell cultures. 
Adenovirus containing the muscle glycogen phosphorylase cDNA linked to 
cytomegalovirus (CMV) immediate early promoter was used to transduce primary 
rat hepatocytes (Gómez-Foix et al, 1992), differentiating myoblasts and non-
dividing mature myotube cells in culture (Baqué et al, 1994). The latter might be 
useful as a gene therapy for the restoration of glycogenolysis in muscle cells from 
patients with McArdle’s disease. Adenovirus has also been used for metabolic 
engineering of pancreatic islets (Becker et al, 1993) and gene transfer and 
expression of recombinant axonin-1 in dorsal root ganglia in vitro (Giger et al, 
1997). 
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Efficacy of adenovirus for in vivo gene delivery was confirmed and 
elaborated by several groups. Initial efforts were directed at delivery of genes to 
the airway epithelia of lungs, since these cells can be specifically targeted by 
intra-tracheal instillation (Rosenfeld et al, 1991). In 1993, the first phase clinical 
trial for cystic fibrosis (CF) was initiated using cystic fibrosis transmembrane 
conductance regulator (CFTR) expressing recombinant adenovirus delivered to 
CF nasal epithelium. In another study, recombinant virus containing the β-gal 
gene was injected into the jugular vein of normal mice resulting in gene transfer to 
approximately 90% of the hepatic parenchyma cells (Herz and Gerard, 1993). 
Chao and co-workers (2002) also reported the use of first generation adenoviral 
vectors to transfer kallikrein gene via intravenous injection, intra-muscular gene 
delivery and carotid artery gene delivery to attenuate blood pressure increase and 
cardiac and renal damage in various animal models. These are crucial for future 
clinical applications in gene therapy for cardiovascular and renal diseases. Gene 
transfer into the brain has also been widely reported. La Salle et al (1993) showed 
that after stereotatic inoculations into rat hippocampus and substantia nigra, 
microglial cells, astrocytes and neurons were found to carry the transgene. In 
addition, adenovirus infecting glial and neuronal cells at the injection site and can 
also be transported in a retrograde manner via axons to a projecting brain area far 
away from the site (Bohn et al, 1999). Virus-mediated gene transfer and 
expression of recombinant axonin-1 are also documented in the dentate gyrus of 
the hippocampus, Punkijke cells of the cerebellum and motonuerones of the facial 
nucleus in vivo (Giger et al, 1997). Promising results were also obtained by Corti 
and co-workers (1999a. 1999b) when they introduced tyrosine hydrolase into the 
  32
dopamine-depleted stratum of a rat model of Parkinson’s disease. It could be seen 
from the vast quantity of scientific studies done, great potential for adenovirus as 
a form of gene therapy is expected.  
 
1.2.2 Tetracycline regulated gene expression 
The tetracycline-controlled (tet-controlled) gene expression system has 
gained increasing popularity since its invention and has been widely employed to 
regulate protein synthesis in cultured cells and in transgenic mice by varying the 
corresponding mRNA synthesis (Gossen and Bujard, 1992). Two types of system, 
tet-on and tet-off, have been used to regulate transgene expression. 
The tet-off expression system (Gossen and Bujard, 1992) (Figure 1.4a) is 
based on regulatory elements of the Tn10-specific tetracycline-resistance operon 
of Escherichia coli. In this operon, transcription of resistance-mediating genes is 
negatively regulated by the tetracycline repressor (tetR). In the presence of the 
antibiotics tetracycline (tet), tetR does not bind to its operators located within the 
promoter region of the operon and allows transcription. By combining tetR with 
the C-terminal domain of VP16 from Herpes Simplex Virus (HSV), known to be 
essential for the transcription of the immediate early viral genes, a hybrid 
transactivator was generated. The transactivator stimulates minimal promoters 
fused to tetracycline operator (tetO) sequences. These promoters are virtually 
silent in the presence of low concentrations of tet (or doxycycline, dox) which is 
an analog of tetracycline), and prevents the tet-controlled transactivator (tTA) 
from binding to tetO sequences.  







































Figure 1.4. Schematic representaion of tetracycline-controlled expression in 
mammlian cells. (a) Tet-off system. (b) Tet-on system. Appropriate promoter-P; 






















tetracycline-responsive transcriptional activator (rtTA) was created by four amino 
acid changes in tet repressor protein (rtetR) and VP16 moiety. In the absence of 
tet (or dox), the transactivator does not recognise its specific DNA target 
sequencetetracycline-responsive transcriptional activator (rtTA) was created by 
four amino acid changes in tet repressor protein (rtetR) and VP16 moiety. In the 
absence of tet (or dox), the transactivator does not recognise its specific DNA 
target sequence. (tetO). Therefore transcriptional activation of the transgene will 
not occur. Addition of tet (or dox) allows the binding of rtTA to tetO, hence 
transcription of the transgene. The minimal promoter construct used in this system 
is identical to that of the tet-off system.  
 Thus, the tet-off system provides a negative control while the tet-on 
system provides a positive control of transgene expression. 
 
1.2.3 Tetracycline-regulated adenovirus expression 
One limitation of tet-controllable expression system for the study and 
analysis of gene function is the tedious task of generating cell lines. Stable 
transfectants have to be generated for every gene and every cell type. This 
problem can be overcome by the use of recombinant adenovirus (Ad) vectors to 
obtain inducible expression, since Ad vectors were known to be able to deliver 
foreign genes efficiently into a wide range of cell types, both in vitro and in vivo. 
The cells under study are co-infected with the adenoviral vector expressing tTA or 
rtTA together with the vector expressing the gene of interest under the control of 
the tet-responsive promoter (Harding et al, 1998; Mizuguchi and Hayakawa, 
2001). Recently a modification to this strategy was described (Corti et al, 1999a; 
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Mizuguchi and Hayakawa, 2002) whereby an Ad vector with a self-contained tet-
regulated expression system was developed. The expression cassette of the gene 
of interest using the tet-responsive promoter was introduced into the E1 deletion 
region, while that of the rTA (or rtTA) was introduced into the E3 deletion 
regions of the vector.  
The tet-controlled expression system has been successfully employed in 
various cells types in vitro such as astrocytes cells, endothelial cell-line derived 
from human liver, HeLa cells and human anaplastic astrocytoma and in brain 
grafts of human neural progenitors (A-Mohammadi and Hawkins, 1998; Corti et 
al, 1999a; Fender et al, 2002; Mizuguchi and Hayakawa, 2002; Mizuguchi et al, 
2003). Their use has also been described in vivo (Harding et al, 1998; Corti et al, 
1999b, Fender et al, 2002; Gu et al, 2002) 
 
1.3 Phosphoproteomics 
Protein phosphorylation is one of the most common protein post-
translational modifications and has been found in nearly all cellular processes. 
This is especially true of the phosphorylation of serine, threonine and tyrosine 
residues and has been recognised as a key event in signal transduction in 
eukaryotic cells (Hunter, 1995). A proteomics approach to protein 
phosphorylation has the advantage of studying all the phosphoproteins in a cell, 
otherwise known as the phosphoproteome, at the same time. Analysis of 
phosphoproteins is not easy for the following reasons (Mann et al, 2002). Firstly, 
the stoichiometry of phosphorylation is generally low as only a small fraction of 
the available intracellular pool of proteins is phosphorylated at any given time due 
  36
to a stimulus. Secondly, the phosphorylated sites on proteins might vary which 
might give rise to different phosphorylated forms. Thirdly, many of the signalling 
molecules are present at low abundance within cells. Fourthly, most analytical 
techniques used for studying protein phosphorylation have a limited dynamic 
range which results in difficulties in identifying minor sites and finally, 
phosphatase could dephosphorylate residues unless precautions were taken to 
inhibit their activity during preparation and purification steps of the cell lysate. 
A common approach used in phosphoproteomics is the in vivo labeling 
of phosphoproteins with inorganic 32P (Graves and Haystead, 2002). 
Phosphoproteomes of cells that had undergone different treatments can be 
analysed by growing these cells in inorganic 32P and then obtaining the cell 
lysates. Differences in the phosphorylation state of proteins can then be examined 
by two dimensional gel electrophoresis (2DE) and autoradiography. Proteins of 
interest are then excised from the gel and microsequenced by mass spectrometry 
(MS). 
As mentioned, one major problem in the study of phosphoproteomics is 
the relatively low copy number of phosphorylated proteins; hence the great need 
for the enrichment of phosphoproteome. Three different approaches have been 
described for phosphoprotein enrichment: (i) immunoaffinity-based methods, (ii) 
immobilised metal affinity chromatography (IMAC) (iii) chemical modification 
and isotopic labelling. In the first approach, phospho-specific antibodies were 
used to immunoprecipitate phosphorylated proteins from cell lysates. Stancato and 
Petricoin (2001), and Gronborg and co-workers (2002) have described enrichment 
by the immunoprecipitation of tyrosine-phosphorylated proteins and 
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serine/threonine-phosphorylated proteins respectively. The second approach, 
IMAC, is a chromatographic technique for phosphoproteins, based on the affinity 
of Fe(III) or Ga(III) for the negatively charged phosphate groups (Posewitz and 
Tempst, 1999; Gaberc-Porekar and Menart; 2001). In the last approach, the 
phosphorylated residues were chemically modified and then isolated via affinity 
chromatography. Studies have been done to modify the phosphorylated serine and 
threonine to carry biotin tags which were then selectively fished out by using 
immobilized streptavidin (Oda et al, 2001). A modification, known as 
phosphoprotein isotope coded-affinity tags (PhIATs), was described by Goshe et 
al (2001) whereby biotin-containing affinity tags with two different masses were 
used to tag pSer and pThr of two differentially treated samples. The samples were 
then combined and the relative intensity of corresponding heavy and light 
peptides is determined by MS. Once the phosphoproteome has been enriched, 
combined use of procedures and tools such as 2DE, Edman degradation and mass 
spectrometry such as nanoflow liquid chromatography-tandem mass spectrometry 
(MS/MS) or matrix-assisted laser desorption ionization time-of-flight (MALDI-
TOF) MS, can be used for peptide identification and phosphorylation site 
identification (Graves and Haystead, 2002). A summary of mass spectroscopy-
based methods used in the study of phosphoproteomics is shown Figure 1.5. In 
some instances, immunoblotting was carried out after 2DE with antibodies against 
specific phosphorylated amino acid residues prior to gel excision (Iwafune et al, 
2002).  
Recently, an innovative method, known as SH2 profiling, was employed 

































Figure 1.5. An overview of techniques for enrichment and analysis of 
phosphorylated proteins or peptides using MS-based detection methods. 
(Mann et al, 2002). 
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battery of SH2 domain probes were used to provide a qualitative and quantitative 
fingerprint, or profile, of the overall state of tyrosine phosphorylation of a protein 




1.4 Objectives of the study 
There are three main objectives to this study: 
1. To establish the Tet-off Adeno-X Expression System in COS-7 cell-line. 
2. To study wild type and mutant CD157-mediated tyrosine phosphorylation 
in COS-7 cell-line via adenoviral infection. 
3. To investigate the overall differential expression of phosphorylated 



































2.1.1 Bacterial strains 
The Escherichia coli strain, DH5α, used in this study was prepared and 
described as in section 2.1.5.1. Long-term storage of bacteria was carried out in 
LB-Broth with 20 % glycerol at -80˚C.  
 
2.1.2 Mammalian cell line 
HEK293 cell lines  
The human embryonic kidney 293 cell-line (HEK293) was obtained from 
the American Type Culture Collection. For short-term storage, cells are suspended 
in freezing media and kept at -80˚C. For long-term storage, cells were suspended in 
the same storage media and kept in liquid nitrogen.  
 
COS 7 cell lines 
COS-7 cell-line was obtained from the American Type Culture Collection. 
Long-term and short-term storage of cells carried out similarly to HEK293 cells. 
 
2.1.3 Plasmids 
pTRE Shuttle Vector 
pTRE Shuttle vector contains a tet-responsive mammalian expression 
cassette. Its Tet Response Element (TRE) is composed of seven direct repeats of a 
42-bp sequence that contains the 19-bp tet O sequence. It contains unique 
restriction sites whereby the gene of interest was cloned into. 
pAdeno-X vector 
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This adenoviral vector is used for the construction of recombinant virus. It 
is derived from the adenovirus type 5 (Ad5) genome and has been altered by 
deleting large portions of the E1 and E3 regions, which are essential for viral 
replication and transcription, and growth and propagation of adenovirus in cell 
culture respectively. Inverted terminal repeats (ITRs) needed for the replication of 
adenoviral DNA flank the E1/E3 deleted Ad5 genome. 
 
2.1.4 Synthetic primers 
The primers used for this study were synthesised by GenSet. Their 







2.1.5 Media and Solutions 
2.1.5.1 Media and Reagents for Bacterial Culture 
 
All media for bacteria were sterilized by autoclaving at 121oC, 115 Lb/in2 
for 20 mins. Thermo-labile supplements such as antibiotics were filter-sterilized 
through 0.22 µm filters before adding to the autoclaved media, which have been 




LB-broth (Luria-Bertani medium) 
1.0 % (w/v) Bacto-tryptone, 0.5 % (w/v) Yeast-extract, 1.0 % (w/v) NaCl. 
The medium was adjusted to pH 7.0 with NaOH prior to autoclaving. 
 
LB agar 
LB-broth contains 1.5 % (w/v) of agar. The medium was autoclaved and 
cooled to 60°C. 25 cm3 of medium was poured into each 10-cm petri-dish. 
 
Antibiotics  
The antibiotics were prepared as stock solutions, sterilised by filtration 
and stored in aliquots at -20°C. 
Ampicillin: stock solution at 100 mg/ml  
Kanamycin: stock solution at 50 mg/ml 
 
2.1.5.2 Media and Reagents for Mammalian Cell Culture 
Complete DMEM medium for COS-7 cell line 
 Incomplete DMEM medium was purchased from the NUMI store 
(National University of Singapore Medical Institute). Prior to use, 
Penicillin/Streptomycin and Tet System Approved Fetal Bovine Serum (heat-
inactivated) was added to make up to a final concentration of 50 U/10 ug per ml 
and 10 % (v/v) respectively.  
Complete MEM-α modification medium for growth of HEK293 cell line 
 
10.1 g of MEM-α medium mixture (Sigma, M0894) and 2.2 g of 
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NaHCO3 was added to 450 ml of autoclaved Milli-Q water. The medium was 
adjusted to pH 7.2 prior to sterilisation by filtration and followed by the addition 
of Penicillin/Streptomycin and FCS (sterile fetal calf serum, heat-inactivated) to 
make up a final concentration of 50 U/10 µg per ml and10 % (v/v) respectively. 
 
Mammalian cell freezing medium 
 
90 % (v/v) of FCS (sterile fetal calf serum, heat-inactivated), 10 % (v/v) 
DMSO (dimethyl sulfoxide). The freezing medium was filter-sterilised and stored 




Tetracycline hydrochloride was prepared as a stock solution of 10 
mg/ml. It was dissolved in 70 % (v/v) ethanol and filter-sterilized and stored as 
aliquots at -20°C. 
 
2.1.5.3 Supplier for reagents and other materials 
Standard analytical grade laboratory chemicals for the preparation of 
general reagents were obtained from Sigma and Merck. Special reagents were 
obtained from:  
Amersham Biosciences 
Cover Fluid 
ECL TM Western blotting detection reagents    
Hyperfilm ECL. 




Adeno-XTM Rapid Titer Kit 
Adeno-XTM Tet-Off TM Expression System 
BDTM Phosphoprotein enrichment Kit 
Tet System Approved Fetal Bovine Serum 
 
Bio-Rad, USA 
Bio-Rad Protein Assay Kit 
Gene Pulser curvette for electroporation 
Nitrocellulose membrane  
Polyacrylamide gel reagents 
SDS-PAGE standard markers 
 
BioSource 
Rabbit polyclonal Anti FAK phosphorylated tyrosine antibodies 
 
Immunotech 
FITC conjugated Anti-CD157 antibody 
 
Pierce, Rockford, IL, USA 
Coomassie  Plus Protein Assay Reagent Kit 
 
Promega, USA 




T4 DNA ligase 
Taq DNA polymerase 
Wizard ®Plus SV Minipreps DNA Purification System 
 
Qiagen, Germany   
QIAamp UltraSensTM Virus Kit 
QIAGEN Plasmid Midi/Maxi Kit 
QIAquick Gel Extraction Kit  
SuperFect Transfection Reagent 
 
Sigma 
α-cyano-4-hydroxycinnamic acid (CHA) 
Monoclonal Anti-β-actin Antibody 
Monoclonal Anti-Phosphotyrosine –Agarose 
Phospholipase C, Phosphatidylinositol-specific 
 
Stratagene, USA 
Site-directed mutagenesis kit 
 
Transduction Laboratories 
Monoclonal anti-phosphotyrosine antibody (clone PY20) 
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2.2 Methods 
2.2.1 Methods for nucleic acids manipulation  
2.2.1.1 Polymerase chain reaction (PCR) 
PCR was used to exponentially subclone, amplify or mutate target DNA 
fragment. The thermostable Taq DNA polymerase (Promega) was used in the 
cycling reactions. Reactions were typically carried out in a total volume of 50 µl. 
The reaction mixtures consisted of 1~20 ng DNA template, 1×PCR buffer, 2 mM 
MgSO4, 0.2 mM dNTP mix, 0.2 µM each primers, 1-2 units of Taq DNA 
polymerase. Prior to thermal cycling, the reaction mix was heated up to 94°C for 5 
mins. Thermal cycling was typically carried out for 25~35 cycles of the following 
profile: 94°C (DNA denaturation), 45~60 s, 45~60°C (primer annealing) 60 s, 
72°C (extension) 1~2 mins. This profile was adjusted depending on the size of the 
amplified DNA, template and primer used. The last cycles had an additional 5 
mins extension time. 
 
2.2.1.2 Site-directed mutagenesis by QuikChange mutagenesis kit 
This kit from Stratagene allows in vitro multiple sites mutagenesis. 
Wild-type CD157 was mutated at two sites: Arg103 was changed to Cys103, and 
Arg184 was changed to Cys184 by changing the DNA sequences from AgA to TgT 
and TCT to TgT respectively. The three-step mutagenesis method is outlined in 
Figure 2.1. Step 1 involved PCR procedure with the two synthetic single-stranded 
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The plasmid, pXJ-31-CD157, was used as the template. Double stranded (ds) 
DNA was then generated with one strand bearing mutations. The nicks were 
sealed by components in the enzyme blend. In step 2, the PCR products were 
treated with restriction endonuclease Dpn I. Only the methylated parental DNA 
was digested by Dpn I endonuclease. In step 3, the mutated single stranded DNA 
was transformed into XL10-Gold ultracompetent cells, where the mutant closed 
circle single stranded (ss) DNA is converted into dsDNA in vivo. The double 
stranded plasmid DNA may then be prepared from the transformants and analysed 
by DNA sequencing to identify the clones bearing both the desired mutations. 
 
2.2.1.3 Restriction endonuclease digestion of DNA 
 Digestion of DNA was carried out in a volume of 20 µl using 
appropriate buffers as recommended by the manufacturers. A typical digestion 
mixture consisted of 2 µg of DNA in TE (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) 
or water, 2 µl of restriction enzyme buffer (10×), 1 µl of restriction enzymes (5-10 
U/µl) and top up with sterile water to a final volume 20 µl. The total amount of 
enzyme used did not exceed 10 % of the total reaction volume so as to prevent 
“star activity” by the enzyme. Restriction mixtures were incubated at optimal 
temperature from 1 hr to several hours. The digested DNA fragments were then 
separated by DNA agarose gel electrophoresis. 
 
2.2.1.4 Concentration of nucleic acids 
  Ethanol precipitation was routinely used to concentrate and purify 
nucleic acids. DNA at concentration of more than 20 µg/ml were readily 
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precipitated with two and a half volumes of absolute ethanol and one-tenth 
volume of sodium acetate (3 M, pH 4.5). The mixture is incubated at -20oC for at 
least 30 mins. The precipitated nucleic acids were then pelleted by centrifugation 
at maximum speed for 30 mins in a microcentrifuge. The pellet was then washed 
with 70 % ethanol at room temperature and air-dried.  
 
2.2.1.5 Phenol:chloroform extraction of DNA 
Phenol:chloroform extraction was the method of choice for removal of 
contaminating proteinaceous materials from DNA preparations. The DNA 
solution was mixed with an equal volume of phenol:chloroform:isoamyl alcohol 
in the ratio of 25:24:1 (v:v:v) by vortexing. The mixture was microcentrifuged at 
full speed for 5 mins at 4oC and the upper (aqueous) layer was transferred to a 
fresh tube. Care was taken not to carry over any proteineous materials at the 
organic and aqueous interface. The DNA solution (aqueous layer) was then 
ethanol-precipitated. 
 
2.2.1.6 DNA ligation 
T4 DNA ligase (Promega), with its appropriate ligase buffer, was used 
for ligation of DNA fragments into vector. Ligation reaction was carried overnight 
at 16°C with vector:insert molar ratio of approximately 1:3 to increase the ligation 





2.2.1.7 Agarose gel electrophoresis of DNA 
 Agarose gel electrophoresis separates DNA molecules according to the 
size of the DNA fragments and the percentage of agarose in the gel used depends 
on the sizes of DNA fragments to be separated. The smaller the DNA molecule, 
the higher percentage (w/v) of agarose the gel should contain, and vice versa. For 
routine gel electrophoresis, the gels were made at 1 % (w/v) with electrophoresis 
grade agarose melted in 30 ml 1×TAE buffer (40 mM Tris-acetate (pH 7.8), 1 mM 
EDTA). The gel was then cooled down to 60°C, added with 0.1 µg/ml ethidium 
bromide and poured into a horizontal gel-casting tray. A comb to create the wells 
for loading DNA samples was inserted immediately into the molten agarose and 
left to set for 30 mins. Once the gel was set, the comb was removed and the gel 
was submerged in an electrophoresis tank containing 1×TAE buffer. DNA 
samples were premixed with the appropriate amount of 6×loading dye and loaded 
into the wells. Electrophoresis was normally carried out at 5 V/cm field strength 
and the migrated DNA bands were visualized under ultra-violet (UV) light.  
 
2.2.1.8 Isolation of DNA from agarose gel 
 The QIAGEN QIAquick Gel Extraction Kit was used for the 
extraction and purification of DNA fragments from agarose gel. The DNA band 
of interest was excised from the agarose gel under the UV light with a clean 
scalpel. The size of the excised gel was minimized by trimming the excess gel. 
The gel slice was weighed and 3 volumes of buffer QG was added to 1 volume of 
gel for DNA fragments from 500 bp to 4 kb and the gel solubilised at 50°C. For 
DNA fragments smaller then 500 bp or larger than 4 kb, 1 volume of isopropanol 
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was added after the solubilisation of agarose gel. DNA suspended in Buffer QG 
was added to a QIAquick spin column. After binding of DNA to the column, the 
column was washed with PE wash buffer. The DNA bound to the column was 
then eluted with appropriate amount of autoclaved Milli-Q water.  
 
2.2.1.9 DNA sequencing 
Cloned DNA fragments were sequenced using the cycle-sequencing 
technique and the sequencing carried out in an automated DNA sequencer. The 
sequencing reaction is essentially a PCR which employed the ABI PRISMTM Dye 
Terminator cycle sequencing kit, an appropriate primer and a good quality dsDNA 
template. Apart from Taq DNA polymerase and the deoxynucleotides, the 
sequencing premix also contained differently fluorescence-tagged dideoxy-
nucleotides, which emitted at their specific fluorescence when hit by the laser. 
The reaction mix comprised of 500 ng of ds template DNA, 4 µl of Terminator 
mix, 4 µl of Half-Term solution, 3.2 pmol of primer and autoclaved Milli-Q water 
top up to a final volume 20 µl.  
The thermal cycling was carried out using the following profiles: 
94°C (DNA denaturation)  30 s 
50°C (primer annealing)  15 s 
60°C (primer extension)  4 mins 




2.2.2 Methods for bacterial culturing and transformation 
2.2.2.1  Preparation of competent cells for electroporation 
 LB agar without any antibiotics, were streaked with competent cells and 
grown overnight. A single colony was picked and inoculated into 5 ml LB 
medium. After overnight growth at 37°C, 3 ml of the bacterial culture was 
inoculated into 500 ml of pre-warmed LB broth in a 2-litre flask and grown till 
OD 600 reached 0.5. The culture was chilled on ice for 10-15 mins and transferred 
into sterile, round-bottom centrifuge tubes. Cells were collected by centrifugation 
at 4000 x g for 20 mins at 4°C. The cell pellet was then resuspended in 500 ml 
ice-cold water and spun again. After washing with ice-cold water, cells were 
washed with 40 ml ice-cold 10 % glycerol. The cell pellet was finally resuspended 
in 1ml ice-cold 10 % glycerol, aliquoted into volumes of 45 µl into pre-chilled 
centrifuge tubes and stored in -80°C. 
 
2.2.2.2 Transformation of bacterial cells by electroporation 
A BioRad MicroPulser was used for high efficiency electroporation of 
plasmid into competent cells. Bacterial cells were thawed and stored on ice. 1 µl 
of ligation product was then added and mixed with the cells. The mixture was 
transferred to a cold 0.2 cm-electroporation cuvette. This was then pulsed once at 
a voltage of 1.8 kV. 1 ml LB medium was immediately added to the cuvette to 
resuspend the cells. Cells were then transferred to a 10 ml-culture tube and 
incubated at 37°C for 1 hr with shaking at 200 rpm. Different volumes of culture 
were plated onto LB plate containing appropriate antibiotics to ensure selection of 
colonies. 
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2.2.3 Preparation of plasmid DNA from bacterial cells 
 Isolation of plasmid DNA was performed on either a small or 
‘miniprep’scale to obtain sufficient material for analysis, or on a large, ‘maxiprep’ 
scale to provide a stock of plasmid for long-term use. 
 
2.2.3.1 Miniprep  
This procedure was carried out using Wizard ®Plus SV Minipreps DNA 
Purification System (Promega). Individual bacterial clones were picked and 
resuspended into separate sterile tubes that contain 3 ml of LB and the appropriate 
antibiotics. The tubes were shaken overnight at 37˚C. The bacterial cells were 
pelleted by centrifugation for 2 mins at 10 000 x g in a microcentrifuge. The 
supernatant was poured off and the tube was blotted upside-down on a paper 
towel to remove excess media. The cell pellet was resuspended in 250 µl of Cell 
Resuspension Solution (50 mM Tris-HCl pH 7.5, 10 mM EDTA, 100 µg/ml 
RNase A). 250 µl of Cell Lysis Solution (0.2 M of NaOH, 1 % SDS) was added 
and mixed by inverting the tube 4 times. 10 µl of Alkaline Protease Solution was 
added and mixed by inverting the tube 4 times and incubated for another 5 mins at 
room temperature. Alkaline protease inactivates endonucleases and other proteins 
released during the lysis of the bacterial cells that can adversely affect the quality 
of the isolated DNA. Finally, 350 µl of Neutralization Solution (4.09 M guanidine 
hydrochloride, 0.759 M potassium acetate, 2.12 M glacial acetic acid) was added 
immediately and mixed well. The bacterial lysate was centrifuged at maximum 
speed (14 000 x g) in a microcentrifuge for 10 mins at room temperature.  
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After centrifugation, the cleared lysate was transferred to the Spin 
Column. The supernatant was spun at maximum speed for 1 min and the 
flowthrough was discarded. The Spin Column was washed with 750 µl Column 
Wash solution twice by centrifugation. The Spin Column was transferred to a new 
sterile microcentrifuge tube and the plasmid DNA was eluted by adding nuclease-
free water to the Spin Column and spun for 2 mins. After elution, the Spin 




Large-scale plasmid DNA preparations were carried out using QIAGEN 
Plasmid Midi/Maxi Kit. Bacterial cells were harvested from 100-200 ml of 
overnight bacterial cultures by centrifugation at 6 000 x g for 15 mins at 4˚C. The 
pellet was resuspended in Buffer P1 and then mixed with Buffer P2. After 
incubation at room temperature for 5 mins, Buffer P3 was added and mixed 
immediately. The sample was incubated on ice for 20 mins and then centrifuged at 
12 000 x g at 4˚C for 30 mins and followed by another 15 mins. The supernatant 
was then applied to the pre-equilibrated QIAGEN-tip 100/500 column and was 
washed twice with Buffer QC. The DNA was eluted with Buffer QF and 
precipitated with 0.7 volume of isopropanol. The precipitated DNA was 
centrifuged at 16 000 x g for 15 mins. After washing with 70 % ethanol and air-
drying, the DNA was re-dissolved in a suitable volume of TE (10 mM Tris-HCl, 1 
mM EDTA, pH 8.0) buffer and stored in –20oC. 
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2.2.4 Mammalian cell culture techniques 
2.2.4.1 Maintenance of cells 
HEK293 cells and COS-7 cells were grown in MEM-α modification and 
DMEM media, respectively. The media were supplemented with 10 % heat-
inactivated FCS, 2 mM L-glutamate, 50 U/ml penicillin and 10 µg/ml 
streptomycin. The cells were cultured at 37˚C in a humidified 5 % CO2 
atmosphere. 
 
2.2.4.2 Storage of frozen cells  
Cells were grown up to late log phase. Adherent cells were trypsinised 
and spun down at 200 x g for 5 mins. Cells were then resuspended in the freezing 
medium at a density of 1 x 106 cells/ml. Aliquots of 1 ml were added to 
polypropylene freezing tubes. The tubes are frozen slowly at 1˚C/min and were 
either stored in -80˚C for short-term storage or in liquid nitrogen for long-term 
storage. 
 
2.2.4.3 Revival of frozen cells 
Frozen stock of cells was thawed rapidly in a 37˚C water bath. The cells 
were transferred to a sterile tissue culture flask and appropriate volume of 
complete culture medium was added. The cells were then incubated in a 37˚C 





2.2.4.4 X-gal staining of cells 
 Cells were washed twice with 1xPBS (8g/l NaCl, 0.2g/l KCl, 0.24g/l 
KH2PO4, 1.44g/l Na2HPO4) and were fixed for 10 minutes at room temperature in 
0.5 % (v/v) glutaraldehyde diluted in PBS. The cells were then washed thrice with 
1xPBS containing 1 mM MgCl2. The cells were incubated with the staining 
solution (1 mg/ml X-Gal, 5 mM K4Fe(CN)6·3H2O, 5 mM K3Fe(CN)6, 1 mM 
MgCl2 in 1xPBS) at 37oC until the desired staining was achieved. Finally, cells 
were washed with 1xPBS and observed under the light microscope. 
 
2.2.5 Recombinant adenovirus production and Tet-off expression in COS-
7 cells 
 Recombinant adenovirus, containing wild-type or mutant CD157, was 
produced using the Adeno-X Tet-Off Expression System from BD 
Biosciences. An overview of the protocol for this system is shown in Figure 2.2. 
 
2.2.5.1 Cloning of full-length of CD157 into pTRE shuttle vector 
Full-length human CD157 cDNA, both wild-type and mutant, was 
amplified using Pfu polymerase and cloned in frame, into the pTRE Shuttle vector 
(BD Biosciences) at Apa I and Not I restriction sites (Figure 2.3). cDNA plasmid 
pUC19-CD157 and pXJ-41-mCD157 was used as template for CD157 and 
mCD157 respectively. The sense and anti-sense primers used were Apa-I-CD157 
and Not-I-CD157. A DNA fragment of about 900 kb was amplified. DNA 

























Figure 2.2. Overview of the Adeno-X Tet-Off Expression protocol. 
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Figure 2.3. Cloning of CD157 into pTRE-Shuttle vector. CD157 cDNA was 
first amplified, digested by Apa I and Not I and inserted into pTRE shuttle vector 
under the control of tetracycline-responsive promoter (PhCMV*-1). PhCMV*-1is made 
up of a group of seven tet O sequences (tetO)7 that have been joined to the 
minimal immediate early promoter of human cytomegalovirus (PminCMV). 
Legends: Multiple cloning sites (MCS), Bovine growth hormone transformed with 
pTRE-CD157 and pTRE-mCD157 was screened and positive colonies were 
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2.2.5.2 Cloning of Tet responsive expression cassette containing CD157 into 
pAdeno-X genome 
The plasmid, pTRE-CD157, was digested with PI-Sce I and I-Ceu I to 
yield the expression cassette containing CD157. This expression cassette was then 
polyadenylation signal (BGH poly A), pUC replication origin (pUC ori), 
Kanamycin resistant gene (Kanr) ligated with Adeno-X viral DNA (BD 
Biosciences) that has already been linearised with PI-Sce I and I-Ceu I (Figure 
2.4). E. coli transformed with pAdeno-CD157 was screened and positive colonies 
were identified by PCR and confirmed by restriction analysis. 
 
2.2.5.3 Production of recombinant adenovirus 
HEK293 cells were seeded at 15 % confluency in T25 culture flask and 
cultured until 60 %~70 % confluency. Before pAdeno-CD157 DNA can be 
packaged, the recombinant plasmid was linearised by digesting with Pac I. After 
purification via phenol:chloroform extraction, 5 µg of linearised plasmid was 
dissolved in 150 µl of serum-free medium (MEM α-modification medium without 
FCS) followed by the addition of 30 µl of SuperFect Transfection Regeant 
(Qiagen). This mixture was incubated for 10 mins at room temperature to allow 
for formation of transfection-complex. HEK293 cells were washed once with 
1xPBS. The transfection complex was then diluted with 1 ml of culture medium 
(containing serum and antibiotics) and added to the T25 flask. The cells were 
incubated with the transfection complexes for 3hrs in a 37°C humidified incubator 

























Figure 2.4. Cloning of Tet-responsive expression cassette into pAdeno-X 
DNA. The tet-responsive expression cassette was first excised by PI-Sce I and I-
Ceu I and subsequently cloned into the linearised pAdeno-X DNA.  
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complexes were removed and cells were washed once with 1xPBS. Fresh growth 
culture medium was then added to the cells. 
The cells were maintained in a 37°C humidified incubator with 5 % CO2 
until cytopathic effect (CPE) was observed. Once CPE is observed, infected cells 
were dislodged from the flask by gentle agitation and transferred to a sterile 15-ml 
conical centrifuge tube. The medium was decanted after centrifugation of 
thesuspension at 1 500 x g for 5 mins at room temperature. The cell pellet was 
resuspended in 500 µl of 1xPBS. Virus was released from the cells by lysing the 
cells with three consecutive freeze-thaw cycles. After the third cycle, the cell 
lysate was collected after a brief centrifugation. 250 µl of this cell lysate was then 
used to infect a fresh culture of HEK293 cells in T25 flask by adding it directly to 
the medium. The cells were incubated as per normal and again, once CPE was 
observed, the adenovirus was collected as before by lysing the cells through three 
freeze-thaw cycles. This viral stock was named the “Primary Amplification” stock 
and was used to prepare High-Titer Stock. The virus stock is kept at –80oC. 
 
2.2.5.4 Preparation of high-titer stocks for adenovirus 
 
 This protocol was used to amplify the recombinant adenovirus and to 
produce additional stocks of the Adeno-X Tet-Off regulatory and Adeno-X TRE-
β-gal control viruses. 
 HEK293 cells were plated in a T75 flask approximately 24 hrs before 
infection. The cells were grown to about 60-70 % confluency. On the day of the 
infection, the culture was replaced with 5 ml of fresh culture medium containing 
the adenovirus to be amplified, added to achieve a multiplicity of infection (MOI) 
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of at least 10. The cells were incubated for 90 mins, after which, 10 ml of fresh 
growth medium was added. Cells were maintained until CPE was observed and 
the virus was isolated using the freeze-thaw method given in Section 2.2.5.3. 
 
2.2.5.5 Confirmation of insert in recombinant adenovirus 
 
Confirmation of the insert in the recombinant adenovirus was carried out 
by first isolating the viral DNA using the QIAamp UltraSens Virus Kit 
(Qiagen). 10 µl of recombinant virus was adjusted to 1ml by adding 1xPBS in a 2 
ml microcentrifuge tube. 0.8 ml of Buffer AC and 5.6 µl carrier RNA solution 
was added and mixed thoroughly with the virus solution, and incubated at room 
temperature for 10 mins. The sample was then centrifuged at 1 200 x g for 3 mins, 
and the supernatant was discarded. Subsequently, 300 µl of Buffer AR, which was 
pre-warmed to 60oC, and 20 µl of proteinase K were added to the pellet and 
thoroughly mixed. This mixture was incubated for 10 mins at 40oC. 300 µl of 
Buffer AB was then added and mixed, and the final lysate was applied to a 
QIAamp spin column. The column was centrifuged for at 250 x g for 1 min for 
binding of the DNA to the silica-gel membrane. The DNA was washed twice with 
Buffer AW1 and AW2 consecutively and finally eluted out with an appropriate 
amount of autoclaved Milli-Q water. 
The adenoviral DNA obtained were then used as template for the PCR to 






2.2.5.6 Determination of adenovirus titre 
Adenovirus titre was determined using Adeno-X Rapid Titer Kit (BD 
Biosciences). Firstly, 1 ml of HEK293 cells (5 x 105 cells /ml) was seeded into 
each well of a 12-well plate. Serial dilution (102 – 106) of virus solution using the 
medium as diluent was performed and 100 µl of each viral dilution was added 
dropwise to each well. A total of 3 replicate was carried out for each dilution. The 
cells were incubated for 48hrs at 37oC in 5 % CO2. After 48 hrs, the medium was 
aspirated and the cells were dried in the laminar hood for 5 mins. Subsequently, 
cells were fixed by ice-cold 100 % methanol and incubated at –20oC for 10 mins. 
The fixed cells were washed thrice with 1 %BSA (w/v) resuspended in 1xPBS 
and were then incubated with mouse anti-hexon antibody 1:1000 in PBS with 1 % 
BSA (w/v) at 37oC for an hour. The cells were again washed thrice and rat anti-
mouse horseradish peroxidase (HRP) conjugated antibody were diluted 1:500 in 
PBS with 1 % BSA, added to each well and incubated at 37oC for an hour. Cells 
were wash thrice with 1 % BSA in 1xPBS, after which, DAB working solution 
was added to each well and incubated at room temperature for 10 mins. DAB was 
removed and PBS was added to each well. A minimum of three fields of brown 
positive cells were counted and the infectious units (ifu)/ml for each well was 
calculated using the following equation:  
   (infected cells/field) x (field/well)    
volume virus (ml) x (dilution factor) 
 
2.2.5.7 Co-infection of COS-7 cells 
COS-7 cells were plated in 6-well plates 12-24 hrs before infection and 
grown to a confluency of about 80 %. Culture medium was removed the next day 
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and 300 µl virus of appropriate dilution of either the recombinant virus (response 
virus) or the control virus (βgal control) and the Tet-Off virus (regulatory virus) 
was added to the centre of each well. The plates were tipped to ensure that the 
viruses were spread evenly over the cells. The ratio of the recombinant virus (or 
the control virus) to the Tet-Off virus was kept at 1:1. The cells were incubated in 
a humidified CO2 (5 %) incubator at 37oC for 4 hrs to allow the virus to infect the 
cells. Fresh complete medium with or without tetracycline was then added. The 
infected cells were maintained for 48 hrs before analysis of transgene expression. 
 
2.2.5.8 Tet-regulated expression of CD157 in COS-7 cells 
 Cells were infected as described in Section 2.2.5.7. After the 4-hr 
incubation with the virus, fresh medium containing different concentrations of 
tetracycline was added to each well. The cells were maintained for approximately 
48 hrs in a humidified CO2 (5 %) incubator at 37oC. Expression of the transgene 
was analysed after 48 hrs. 
 
2.2.6 Expression, purification and analysis of CD157 
2.2.6.1 Expression of CD157 in COS-7 cells 
COS-7 cells were infected as described in Section 2.2.5.7. 48 hrs post 
infection, these CD157 recombinant virus-infected cells were washed with 1xPBS 
and then detached from the culturing flask wall with 1xPBS containing 1.0 mM 
EDTA. The cells were collected by spinning at 1 000 x g for 1 min and lysed in 
40 µl of reducing 2x Laemmli sample buffer (0.125 M Tris-HCl, pH 6.8, 20 % 
sucrose (w/v), 10 % SDS (w/v), 10 % β-mercaptoethanol (v/v), 0.01 % 
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bromophenol blue (w/v)) by boiling for 5 min. CD157 were analysed by 
immunoblotting using a rabbit polyclonal anti-CD157 antibody. 
 
2.2.6.2 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
 SDS-PAGE resolving gels of 8 % (and 10 %), and stacking gel of 5 % 
were prepared as follow: 
Stock solution /ml 8 % Resolving gel /ml 
(10 % Resolving gel) 










1.5 M Tris-HCl (pH8.8) 3.80 --- 
1 M Tris-HCl (pH6.8) --- 0.38 
10 % SDS 0.150 0.03 
10 % APS 0.150 0.03 
TEMED  0.006 0.002 
Final volume 10.0 3.0 
 
Freshly-made ammonium persulphate (APS) and TEMED were added to 
the solution immediately before casting. The separating gel solution was poured 
into the vertical gel caster (Bio-Rad) first and left to set at room temperature 
before pouring in the stacking gel and placing the comb. Once the stacking gel 
was set in the caster, it was fixed into the vertical electrophoresis unit. Protein 
samples were mixed and boiled for 5 min with protein loading buffer and loaded 
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into the wells of the gel. Electrophoresis was carried out at constant voltage of 
100 V until the protein sample entered the resolving gel after which it was 
increased to 200 V. After electrophoresis, the gel was used for Western blotting. 
 
2.2.6.3 Western Blotting 
Protein samples were separated on SDS-PAGE as described in Section 
2.2.6.2 and transferred onto nitrocellulose membrane using a wet 
transelectroblotting system (Bio-Rad Inc., England) at a low voltage of 80 V for 2 
hr. The transfer buffer is made up of 150 mM Tris-HCl, 39 mM glycine and 20 % 
methanol. The membrane was then blocked in TBS-T (20 mM Tris, 137 mM 
NaCl, pH 7.5, 0.1 % Tween 20 (v/v)) containing 5 % non-fat milk (w/v) or 1 % 
BSA (w/v) for 1 hr. After incubation in the appropriate primary antibody for 1-2 
hrs at room temperature, the membrane was washed thrice with TBS-T, 15 mins 
each, to remove excess antibodies. Then, the membrane was incubated in HRP-
conjugated secondary antibody for 1 hr at room temperature. The unbound 
secondary antibodies were washed away with TBS-T thrice, 10 mins each. The 
immunoreactive bands were detected by enhanced chemiluminescence (ECL) 
reagent using a KODAK film processor. 
 
2.2.6.4 Stripping and reprobing of membranes 
 After each immunodetection, the bound primary and secondary 
antibodies can be removed from the membrane, which then can be reprobed with 
different antibodies. The membrane was submerged in stripping buffer (100 mM 
2-mercaptoethanol, 2 % SDS, 62.5 mM Tris-HCl, pH 6.7) and incubated at 50°C 
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for 30 mins with occasional agitation. It was then washed with large volumes of 
TBS-T at room temperature. The membrane was subsequently blocked in 5 % 
non-fat milk (or 1 % BSA) in TBS-T and was ready to be reprobed by a different 
antibody using the same protocol described in Section 2.2.6.3. 
 
2.2.6.5 PI-PLC digestion and Triton X-114 partitioning 
PI-PLC (phosphatidylinositol-specific phopholipase C) digestion and 
Triton X-114 partitioning was performed to show the GPI anchorage of 
recombinant CD157. The PI-PLC digestion was carried out by incubating the cells 
for 30 mins at 37°C with 4U/ml of PI-PLC in 1xPBS containing a protease 
inhibitor cocktail (0.1 mM PMSF, 10.0 µg/ml of aprotinin and leupeptin, 50.0 
µg/ml of soybean trypsin inhibitor). The digestion buffer and cells were separated 
and subjected to SDS-PAGE and western blotting, respectively, to detect CD157.  
For Triton X-114 partitioning, cells were lysed in PBS/2 % triton X-114 
containing the protease inhibitor cocktail at 4°C for 10 min. The lysate was 
centrifuged at 10 000 x g for 10 min at 4°C and the resulting supernatant was 
partitioned into aqueous and detergent phases by incubation at room temperature 
for 5 mins. After spinning at 2 000 x g for 1 min, the two phases were collected 
separately. Samples from the two phases were subjected to immunoblotting for 
the detection of CD157. 
 
2.2.6.6 Confocal microscopy of CD157 expression and localisation 
Confocal microscopy was performed using a Carl Zeiss LSM 510 
confocal microscope, equipped with a 40 x Fluar objective (NA = 1.3), 63 x Plan-
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Apochromatic objective (NA = 1.4) and a 100x Fluar objective (NA = 1.3), oil 
immersion. COS-7 cells were grown on glass coverslip in culture medium and 
were infected with both response and regulatory virus as described in Section 
2.2.5.7. 48 hrs post infection, cells were washed thrice with 1xPBS, 5 mins each, 
before fixing with 4 % of paraformaldehyde (freshly prepared and pre-warmed to 
37oC) for 20 mins at 37oC. Fixed cells were washed thrice with 1xPBS, 5 mins 
each, to remove excess paraformaldehyde, and then permeabilised with 0.1 % of 
Triton X-100 for 10 mins. Coverslips were incubated for 1 hr in blocking buffer 
(3 % BSA, 0.1 % Triton X-100 in 1xPBS), then incubated for another hour with 
monoclonal CD157-FITC conjugated (RF3-FITC conjugated) antibody diluted to 
an appropriate concentration in blocking buffer. The coverslips were then washed 
thrice, 5 mins each with 1×PBS. Cells were then stained with 4 µg/ml propidium 
iodide in 1×PBS for 5 mins and washed with 1×PBS. Slides were mounted with 
VECTASHIELD mounting medium (Vector Laboratories, CA) onto glass slides 
and sealed with nail polish. 
 
2.2.6.7 Flow cytometry of COS-7 cells expressing CD157 
 Cells were harvested as described in Section 2.2.6.1. The cells were then 
fixed in 4 % paraforameldyde for 20 mins at 37oC. About 1x106 cells were 
incubated with 10 µl of monoclonal CD157-FITC conjugated (RF3-FITC 
conjugated) antibody in 1xPBS for 1 hr at 4oC in darkness. After washing twice 
with 1xPBS, cells were resuspended in PBS. Fluorescence of at least 10 000 cells 




2.2.7 CD157-mediated tyrosine phosphorylation assay 
COS-7 cells grown in 6-well plates were infected as described in Section 
2.2.5.7. 24 hrs post infection, cells were washed with serum-free medium and 
were maintained in this medium at 37oC, 5 % CO2. After serum starvation for 24 
hrs, cells were washed twice with 1xPBS and lysed with lysis buffer (PBS 
containing 1 % Triton X-100 (v/v), 0.1mM phenylmethylsulfonyl fluoride 
(PMSF), 10.0 µg/ml of aprotinin and leupeptin, 50.0 µg/ml of soybean trypsin 
inhibitor (SBTI) and 1.0 mM sodium orthovanadate) on ice for 1 hr. The lysate 
was then pre-cleared by centrifugation at 10 000 x g for 15 mins at 4°C. The total 
protein content of the precleared lysate was determined by Bradford protein assay 
(Bio-Rad) with bovine serum albumin as a standard, according to manufacturer’s 
instructions. Protein concentrations of cell lysate from cells undergoing different 
treatments were normalized before the addition of 15 µl of anti-phosphotyrosine 
agarose beads (Sigma). Binding was carried out overnight at 4°C on a rotating 
platform. The beads were washed thrice with wash buffer (lysis buffer without 
Triton X-100). Laemmli sample buffer was then added to the beads, boiled for 5 
mins and loaded onto SDS-PAGE. The phosphorylated proteins were analysed by 
immunoblotting using a monoclonal phosphotyrosine antibody or various 
phosphotyrosine-specific anti-FAK polyclonal antibodies. 
 
2.2.8 Phosphoproteomics 
2.2.8.1 Enrichment of phosphoproteins 
Enrichment    of    phosphoproteins    was    carried    out    using    BD   
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Phosphoprotein Enrichment Kit (BD Biosciences). This protocol allows proteins 
that carry a phosphate group on any amino acid to be selectively bound by the 
Phosphate Metal Affinity Chromatography (PMAC) Resin.  
Cells grown in T175 flasks were infected as described in Section 2.2.5.7 
with the amount of viruses and culture medium used scaled up proportionately. 
150 mg of cells were harvested and washed thrice with 1xPBS. The cells were 
then freeze in a –80oC freezer, resuspended in Buffer A, and followed by 
incubation on ice for 10 mins. Cell lysate were centrifuged at 10 000 x g for 20 
mins at 4oC to pellet any insoluble material. The supernatant was then added to 
the phosphoprotein affinity column. The column, together with the sample, was 
gently agitated at 4oC for 20 mins on a platform shaker to allow phosphorylated 
proteins to bind. The resin in the column was then allowed to settle and non-
phosphorylated proteins to flow out. Subsequently, the column was washed four 
times with Buffer A. The bound phosphorylated proteins were then eluted with 5 
ml of Buffer B.  
 
2.2.8.2    Buffer exchange for the phosphorylated proteins  
 Buffer B, in which the phosphorylated proteins were in, is of a very high 
salt content which would interfere with subsequent 2DE and hence, the need to 
exchange Buffer B to Tris buffer (20 mM Tris-HCl ,pH 8.0 and 1 mM sodium 
orthovanadate). This was achieved by first concentrating the original 
phosphorylated protein mixture using Centriplus YM-10 (Millipore), that has a 
cut-off point of 10 kDa, to a volume of 200 µl. 2ml of Tris buffer was added to 
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this sample and the volume was reduced to 200 µl again. This process was 
repeated twice until most of Buffer B was exchanged for Tris buffer. Volume of 
the proteins was reduced to 100 µl in the final spin. This final protein sample was 
then diluted with modified rehydration buffer (7 M urea, 2 M thiourea, 4 % 
CHAPS) in a ratio of 1:1 to provide a reducing condition for long-term storage of 
proteins at -80oC. Protein estimation of the phosphorylated proteins was carried 
out using Coomassie Plus Protein Assay Reagent Kit (Pierce) with the bovine 
serum albumin provided as the standard. 
 
2.2.8.3 Two dimensional electrophoresis 
2.2.8.3.1 First dimension (Isoelectric Focusing) 
The first-dimensional isoelectric focusing (IEF) was performed on 
precast 7 cm, linear pH 3-7 IPG strips at 20oC with a maximum current setting of 
50 µA/strip using Amersham Biosciences IPGphor IEF unit. The strips were 
rehydrated overnight in ceramic strip holders in 250 µl of rehydration buffer 
containing 7 M urea, 2 M thiourea, 4 % CHAPS (w/v), 1 mM PMSF, 20 mM 
dithiothreitol (DTT), 0.5 % IPG buffer and trace amounts of bromophenol blue. 
The amount of protein loaded was about 5 or 10 µg. IEF was carried out using the 
following conditions: i) 100 V, 200 Vhrs; ii) 200 V, 200 Vhrs; iii) 500 V, 250 
Vhrs; iv) 1000 V, 500 Vhrs; v) 1000-8000 V, 2250 Vhrs and vi) 8000 V, 12 000 
Vhrs. Voltage increases were performed on “step-wise” basis for all the steps 
except for step v which was performed using the “gradient” mode. The strips were 





2.2.8.3.2 Second dimension (SDS-PAGE) 
The strips were subjected to two equilibration steps before the second 
dimensional SDS-PAGE. The first was with an equilibration buffer containing 6 
M urea, 30 % glycerol, 2 % SDS, 50 mM Tris-HCl (pH 6.8) and 1 % (w/v) DTT. 
The second step was with a buffer containing 6 M urea, 30 % glycerol, 2 % SDS, 
50 mM Tris-HCl (pH 8.8) and 2.5 % (w/v) iodoacetamide (IAA) to alkylate thiol 
groups of the proteins. After the strips were transferred onto the second 
dimensional SDS-PAGE gel, the strips were sealed with 0.75 % agarose dissolved 
in electrophoresis running buffer with trace amount of bromophenol blue. SDS-
PAGE was performed on 10 % PAGE gels at constant current of 15 mA. 
 
2.2.8.4 Silver stain 
Silver staining procedure was adapted from Mortz et al (2001) with 
some modifications. 
After electrophoresis, gels were fixed in the fixing solution (50 % 
methanol (v/v), 12 % acetic acid (v/v), 0.05 % formalin (v/v)) overnight. They 
were washed in 35 % ethanol (v/v) thrice and then sensitised with the sensitising 
solution (0.02 % sodium thiosulphate (w/v)) for 2 mins. They were then rinsed 
with 3 changes of Milli-Q water for 5 mins each before incubating in the staining 
solution (0.2 % silver nitrate (w/v), 0.076 % formalin (v/v)) for 20 mins. After 
another 2 washes with Milli-Q water for 1 min each, the gels were developed in 
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the developing solution (6 % sodium carbonate (w/v), 0.004 % sodium 
thiosulphate (w/v), 0.05 % formalin (v/v)) until the desired intensity was 
achieved. The colour development was stopped by incubation in the stop solution 
(1.46 % sodium-EDTA (w/v)) for 20 mins. The gels were finally washed with 
Milli-Q water for 3 times, 5 mins each. All the above procedures were carried out 
with shaking on a platform orbital shaker. 
 
2.2.8.5 In-gel proteolytic digestion 
The protein spots were manually excised from gels and incubated at 4oC 
in 150 µl of 2.5 mM ammonium bicarbonate and 50 % acetonitrile (v/v) overnight 
in microcentrifuge tubes. After incubation, fresh 150 µl of the same solution was 
replaced and incubated with shaking at 37oC for 20 mins. The solution was 
discarded and gels were vacuum-centrifuged for 5 mins. Reduction of the spots 
was carried out by incubating the gels with 10 mM DTT in 100 mM ammonium 
bicarbonate at 56oC for 1 hr. Alkylation was performed with 55 mM IAA in 100 
mM ammonium bicarbonate at room temperature in the dark for 45 mins. IAA 
was discarded and washed with 100 mM ammonium bicarbonate at 37oC for 
10mins followed by dehydration with acetonitrile with incubation at room 
temperature for 10 mins. The above wash and dehydration steps were repeated 
twice. The spots were finally dried in Speedvac for 5 mins. Enzymatic digestion 
was then carried out by first incubating the spots with 5 µl of 20 µg/ml of trypsin 
(in 5 mM ammonium bicarbonate, 10 % acetic acid) for 10 mins, and then adding 
5 µl of 50 mM ammonium bicarbonate to allow overnight digestion at 37oC.The 
cleaved peptide fragments were extracted out of the gel matrices with acidic and 
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organic solvents by passive diffusion after the digestion. The digestion buffer was 
acidified with 10 µl of 0.1 % TFA, 50 % acetonitrile (v/v). The gels were 
sonicated for 20 mins to further enhance peptide extraction. 
 
2.2.8.6 MALDI-TOF-MS  
0.5 µl of the extracted peptide mixture was crystallised with 0.5 µl of 
freshly prepared matrix solution (10 mg/ml CHA, 0.1 % TFA (w/v) and 50 % 
acetonitrile) onto the MALDI sample plate. The samples were then air-dried. 
Mass information of the peptides was obtained using a MALDI TOF-MS 
Voyager-DE STR from PerSeptive Biosystems. TOF spectra were acquired over 
the m/z range of 700-3000 under the delayed extraction and reflector mode. All 
spectra were internally calibrated upon acquisition using two of the trypsin 
autodigest fragments (842.5100 and 2211.1140 m/z peaks). Trypsin autolytic 
peaks and other contaminants such as keratin or matrix were excluded from the 
peak list for database search. The peptide masses were searched against SWISS-
PROT and NCBI non-redundant databases using the software, MS-FIT (Protein 
Prospector). The MS-FIT search was performed with the following parameters: all 
molecular weight range; all pI range; oxidation of methionine, acetylation of N-
terminus, caboxyamidomethylation of cysteine, and phosphorylation of serine, 
threonine and tyrosine. Positive identification of protein was assigned only if at 
least four peptide masses matched a hit in the database and within a mass 
tolerance of 50 ppm or lower, matched peptide masses were evenly distributed 
through the amino acid sequence, identified proteins’ molecular weights and pIs 
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In this series of experiments, we attempt to establish the Adeno-X Tet-
off Expression System (BD Biosciences) in COS-7 cell-lines to express CD157 
and mCD157. CD157 was mutated and both CD157 and mCD157 was cloned into 
the respective vectors for transfection into HEK293 cells for recombinant virus 
production. We went further to confirm that CD157 (and mCD157), using such a 
system, was correctly expressed and localised using immunofluorescence, PI-PLC 
treatment and Triton X-114 partitioning. Efforts were also made to access the 
efficiency of the tet-control and the expression of CD157 in COS-7 cells using 
such a system. 
 
3.2 Results 
3.2.1 Site-directed mutagenesis of CD157 
 Wild-type CD157 was mutated at two sites: Arg103 and Arg184 to Cys103 
and Cys184 respectively by mutation of the codons from AgA to TgT and TCT to 
TgT at the respective sites. Results from our lab previously showed  that a soluble 
form of CD157 (sCD157) with mutations at these two sites exhibited an increase 
in the cyclase activity, at least 10 times as compared to the wild-type CD157 (data 
not shown). The primers, CD157M103A and CD157M184A (sequence shown in 
Section 2.1.4) containing the mutations, were used, together with the plasmid 
pXJ41-CD157 as template. A total of 4 clones of transformed XL1-Blue cells 
were screened using PCR and restriction analysis with EcoR I and Kpn I was 
carried out on the putative positive clones for confirmation of the presence of the 
CD157 sequence. The mutations were later confirmed by DNA sequencing (data 
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not shown). Only clone 3 and 4 showed the correct mutations and clone 3 was 
used in all subsequent experiment. 
 
3.2.2 Cloning of full-length wild type and mutant CD157 into the pTRE 
Shuttle vector 
The full-length coding sequence for human wild-type and mutant CD157 
(mCD157) was amplified by PCR using the primer pair, Apa-I-CD157 and Not-I-
CD157 (sequences shown in Section 2.1.4) with pUC19-CD157 and pXJ41-
mCD157 as respective templates. The program settings for the PCR were as 
follows: i) 95oC for 3 mins, ii) 95oC for 1 min, iii) 60oC for 1 min, iv) 72oC for 2 
mins, v) 72oC for 5 mins. Step ii to iv were repeated for 30 cycles before 
proceeding to step v. DNA fragments of 959 kb were amplified in both cases as 
shown in Figure 3.1. Both the PCR products and pTRE-Shuttle vector were 
separately digested with Apa I and Not I restriction enzymes. The digests were 
analysed by agarose gel electrophoresis (Figure 3.2). Respective PCR products 
and vector DNA bands were excised from the gel and purified. The digested 
products were ligated into the multiple cloning sites (MCS) of the digested pTRE-
Shuttle vector between the Apa I and Not I restriction sites. E. coli bacterial cells 
DH5α were transformed with the ligated products respectively and the 
transformants were selected on kanamycin-containing LB-plates. Transformed 
colonies were randomly picked and screened by PCR (Figure 3.3a). Putative 
clones were then further confirmed by restriction analysis with Apa I and Not I 





















Figure 3.1. DNA Electrophoresis of PCR products. Both human CD157 cDNA 
and mCD157 were amplified by using the appropriate primers which gave 
products of ~900 bp. Lane 1: 1 kb marker, Lane 2: CD157 cDNA, Lane 3: 
mCD157 cDNA  
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Figure 3.2. Electrophoresis of restriction enzyme-treated PCR products and 
pTRE-Shuttle vector. Both the PCR products and the vector were subjected to 
Apa I and Not I digestion. (a) CD157 cDNA and pTRE Shuttle vector. Lane 1: 
100 bp marker, Lane 2: 1 kb marker, Lane 3: CD157cDNA, Lane 4:  Vector. (b) 
mCD157 cDNA and pTRE Shuttle vector. Lane 1: 100 bp marker, Lane 2: 
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Figure 3.3. DNA gels. (a) PCR-screen of putative bacterial colonies containing 
pTRE-WTCD157 (Panel A) and pTRE-mCD157 (Panel B). A total of 10 colonies 
and 14 colonies were screened for CD157 and mCD157 respectively. All the 
clones screened showed positive results. Lane 1 of both gels: 1kb marker, Lane 2 
of both gels: positive control whereby pUC19-CD157 was used as the template. 
Remaining lanes: all putative bacterial clones. (b) Restriction analysis with Apa I 
and Not I of a representative clone selected from each of pTRE-CD157 and 
pTRE-mCD157 clones. Lane 1: 1kb marker, Lane 2: pTRE-CD157, Lane 3: 
pTRE-mCD157 
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vector were later confirmed by DNA sequencing. A confirmed clone from each 
was selected for subsequent cloning into pAdeno-X genome. 
 
3.2.3 Cloning of Tet responsive expression cassette, containing CD157 
sequence, into the pAdeno-X genome 
 Large-scale preparation of the plasmids, pTRE-CD157 and pTRE-
mCD157, was first carried out. The plasmids were digested with PI-Sce I and I-
Ceu I to yield the expression cassettes containing CD157 and mCD157 sequences 
respectively. The expression cassettes were ligated with linearised Adeno-X viral 
DNA. DH5α E. coli bacterial cells were transformed with each of the ligated 
products and the transformants were selected on ampicillin-containing LB-plates. 
A total of 20 transformed colonies were randomly picked for each of CD157 and 
mCD157, and screened by PCR. These putative clones were then further 
confirmed by restriction analysis with PI-Sce I and I-Ceu I restriction enzymes. A 
confirmed clone from each of CD157 and mCD157 was used for all subsequent 
work. 
 
3.2.4 Confirmation of presence of insert and production of recombinant 
adenovirus 
 Large-scale preparation of pAdeno-CD157 and pAdeno-mCD157 was 
carried out. The plasmids were linearised with Pac I restriction enzyme, purified 
and subsequently transfected into HEK293 cells as previously described in 
Section 2.2.5.3. About a week after transfection, CPE was observed (Figure 3.4).  





































Figure 3.4. Cytopathic effect of adenovirus on HEK293 cells. (a) Uninfected 
HEK293 cells are adherent and maintained a fibroblastic morphology. (b) CPE 
was observed for HEK293 cells infected with adenovirus. The cells rounded up, 
but remained attached to the substratum and appeared to be more refractive as 
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During CPE, cells rounded up but remained attached to the flask, and appeared to 
be more refractive. The recombinant viruses were collected and used for another 
round of infection. The viruses collected from this second round of infection were 
harvested and labelled as “Primary Amplication Stocks” which would be used for 
all subsequent amplication of high-titre stocks.  
 Prior to large-scale amplification of the recombinant virus, confirmation 
of presence of CD157 and mCD157 sequences, and the titering of the viruses 
were performed. Adenoviral recombinant DNA was isolated and PCR carried out 
(Section 2.2.5.5). DNA electrophoresis of the PCR products is shown in Figure 
3.5. 
 Titres of the amplication stocks were determined as described in Section 
2.2.5.6. The virus stock was serially diluted 102– 106 times and the diluted virus 
was used to infect the cells. Duplicate was carried for each virus concentration. 
This method takes advantage of the production of viral hexon proteins. 48 hrs 
after infection, the infected cells were stained with anti-adenovirus hexon proteins 
primary antibody and detected after a secondary antibody conjugated with HRP, 
to amplify the signal. The stained cells were observed under a phase-contrast light 
microscope under an objective lens of 20x. Each stained cell corresponds to a 
single infectious unit. At least three fields of brown positive cells (Figure 3.6) 
were randomly selected and counted, and the average found. The titre of the virus 
was hence calculated after taking into consideration the number of fields that can 
be observed using a 20x objective lens in each well, volume of virus used for each  
 
 












Figure 3.5. Confirmation of the inserts in the recombinant adenovirus. Viral 
DNA was isolated and the used as template for the amplication of (a) 
CD157cDNA and (b) mCD157. The PCR products were analysed using DNA gel 
electrophoresis. In (a), Lane 1: 1kb marker, Lane 2: Positive control with pUC19-
CD157 as template, Lane 3: PCR product with viral DNA isolated from CD157 
recombinant virus as template. In (b) Lane 1: 1kb marker, Lane 2: Positive control 
with pUC19-CD157 as template, Lane 3: PCR product with viral DNA isolated 
from mCD157 recombinant virus as template. 
  
(a) (b) 









Figure 3.6. A field of positive cells. Different dilutions of CD157 recombinant 
adenovirus were used to infect HEK293 cells and developed by the Adeno-X 
Rapid Titer method. Infected cells were stained brown. The cells in the figure 
were infected with a virus dilution of 104. The cells were viewed under a phase-
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well and the dilution factor of the virus. Once the titres of both CD157 and 
mCD157 recombinant virus primary amplification stocks were determined, the 
virus was used to amplify the virus stock by infecting more HEK293 cells at  
aminimum multiplicity of infection (MOI) of 10 (Section 2.2.5.4). MOI refers to 
the ratio of infectious units to the cells present. After each amplification 
procedure, PCR was carried out to confirm the presence of the CD157 or 
mCD157 sequences in the recombinant virus amplified and the titre of each stock 
was determined. The titre of each amplified stock is typically in the range of ~109 
ifu/ml. 
 
3.2.5 Investigation of the susceptibility of COS-7 cells to adenovirus 
infection 
Co-infection of COS-7 cells with control virus (β-gal virus) and the Tet-
Off virus (regulatory virus) were performed as described in Section 2.2.5.7. The 
ratio of the control virus and the Tet-off virus were kept at 1:1. Two MOIs were 
used to infect the cells: at MOI of 5 and MOI of 10. 48 hrs post infection, the cells 
were fixed and stained with x-gal (Section 2.2.4.4). Cells expressing β-
galatosidase would be stained blue (Figure 3.7). It was observed that infection at 
MOI of 10 gave a higher proportion of infected cells (data not shown). 
 
3.2.6 Expression and localization of CD157 and mCD157 in COS-7 cells 
via adenovirus infection 
 CD157 was expressed in COS-7 via adenovirus mediated infection as 
described in Section 2.2.5.7. To determine the optimal MOI for CD157 expression 
























Figure 3.7. X-gal staining of COS-7 cells. The COS-7 cells were co-infected 
with the βgal control virus and Tet-off regulatory virus at an MOI of 5. Cells were 
fixed and stained 48hrs post infection. Infected cells were stained blue due to the 
expression of β-galactosidase while uninfected cells remained unstained. The cells 
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via adenovirus infection, a range of MOI from 5 to 100 was carried out. CD157 
was harvested 48 hrs after infection and analysed by immunoblotting with a rabbit 
polyclonal anti-CD157 antibodies after SDS–PAGE under reducing conditions 
(Section 2.2.6.1- 2.2.6.3). After detection with anti-CD157 antibodies, the 
membrane was stripped and reprobed with monoclonal anti-β-actin antibodies. 
Since β-actin is constitutively expressed in cells, it was used as an internal 
control. From the western blot and graph shown on Figure 3.8 and 3.9 
respectively, it was seen that the optimal MOI for CD157 is 10. Hence, all 
subsequent adenovirus-mediated infections were carried out at an MOI of 10.  
 To check whether mCD157 could be properly expressed in COS-7 cells, 
COS-7 cells were co-infected with both mCD157 recombinant virus and Tet-off 
virus and Western blotting was carried out as described above. It was shown that 
mCD157 was indeed, properly expressed in COS-7 cells as seen in the western 
blot in Figure 3.10. 
 In order to confirm that CD157 expressed via adenovirus-mediated 
infection is correctly expressed as a GPI-anchored protein, PI-PLC digestion and 
Triton-X 114 partioning were carried out as described in Section 2.2.6.5. Western 
blotting results confirmed that CD157 thus expressed, was indeed a GPI-anchored 
protein (Figure 3.11, 3.12) expressing on the outer membrane of the cells. In 
addition, immunofluorescence staining of cells expressing CD157 and mCD157 
(Section 2.2.6.6), also gave given unequivocal evidence that both CD157 and 
mCD157 were correctly expressed on the cell membrane (Figure 3.13). 
 
 



















Figure 3.8. Optimisation of the multiplicity of infection (MOI) of adenovirus 
on COS-7 cell line. COS-7 cells were infected with CD157 recombinant virus 
and Tet-Off virus at different MOI. After SDS-PAGE and transblotting onto 
nitrocellulose membrane, the membrane was blocked with 5% non-fat milk in 
TBS-T at 4oC overnight. Primary and secondary antibody was diluted 1:1000 and 
1:2500 respectively with the blocking agent for immunoblotting of both CD157 
and  β-actin. Detection was carried using ECL (Amersham). Lane 1: Uninfected 
cells, Lane 2: Cells infected at MOI of 5, Lane 3: Cells infected at MOI of 10, 
Lane 4: Cells infected at MOI of 20, Lane 5: Cells infected at MOI of 50, Lane 6: 
Cells infected at MOI of 100, Lane 7: Negative control, cells infected with β-gal 
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Figure 3.9. Graph showing optimisation of MOI for adenovirus-mediated 
CD157 expression. CD157 was not expressed in uninfected cells and control 
virus infected-cells. Experiments were done in triplicates. Results were obtained 
by phosphoimaging of the bands in the western blots and have been presented as 
the “mean ± SD”. PIU: Phosphorimaging units 
 
*A significant difference between MOI of 5 and 10 at P< 0.01.  
** No significant difference between the MOIs at P < 0.05. 
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Figure 3.10. Western blot of mCD157. COS-7 cells were infected with 
recombinant mCD157 virus and Tet-off virus at MOI of 10. Lane 1: Negative 
control, cells were infected with β-gal control virus and Tet-Off regulatory virus, 
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Figure 3.11. PI-PLC treatment of intact cells expressing CD157. PI-PLC was 
used to digest the GPI-anchor of CD157. CD157 was found in the supernatant 
after PI-PLC treatment but not before that, showing that CD157 is indeed attached 
to the outer cell surface via a GPI-anchor. 
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Figure 3.12. Trition-X 114 partitioning of the adenoviral mediated CD157 
expression in COS-7 cells. CD157, being GPI anchored, is partitioned into the 
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3.2.7 Tet-regulated control of adenovirus-mediated expression of CD157 
 
 COS-7 cells were infected with CD157 recombinant virus and Tet-Off 
response virus at MOI of 10 (Section 2.2.5.7). After incubation of the cells with 
adenovirus for 4 hrs, cells were washed and medium containing different 
concentrations were added. The cells were maintained as per normal in tet-
containing medium for the next 48 hrs. Cells were harvested and analysed for 
CD157 using immunoblotting (Section 2.2.6.1- 2.2.6.3). Western blot results 
showed that expression of CD157 was at its maximum when tet was not added 
and was totally switched off at a low concentration of only 0.01 µg/ml (Figure 
3.14). As observed from Figure 3.15, there was approximately a half-fold 
decrease of protein expression for every 10-fold increase of tet concentration 
added into the culture medium. 
 
3.2.8 High efficiency of introduction of CD157 gene via adenoviral-
mediated infection 
Cells were infected as described previously (Section 2.2.5.7) and 
analysed using flow cytometry as described in Section 2.2.6.7. The FITC-
conjugated anti-CD157 mAb antibody, RF3, was used to stain both CD157 virus-
infected and β-gal virus-infected cells. Efficiency of introduction and expression 
of transgene via adenovirus was expressed as a percentage: the fluorescence 
intensity of CD157 virus-infected cells over the fluorescence intensity of β-gal 
virus-infected cells. The result is presented as “mean ± SD” of triplicate 
experiments. Efficiency was found to be very high, at 82.4 ± 7.1 %. 




























Figure 3.14. Tet-dosage dependent gene expression of CD157. Dose-dependent 
CD157 expression in COS-7 cells was carried out via immunoblotting detection. 
Concentration of yet used ranges from 0 µg/ml to 10 µg/ml. Expression was found 
to be totally switched off at 0.01 mg/ml. To ensure equal loading of proteins, β-
actin was used as an internal control. All cells were infected with the CD157 
recombinant virus except for Lane 1, which were uninfected. Lane 1 and Lane 2: 
0 µg/ml of tet , Lane 3: 0.0001 µg/ml of tet, Lane 4: 0.001 µg/ml of tet, Lane 5: 
0.01 µg/ml of tet , Lane 6: 0.1 µg/ml of tet, Lane 7: 1 µg/ml of tet and Lane 8: 10 
µg/ml of tet 
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Figure 3.15. Graph showing Tet-regulated expression of CD157. CD157 was 
absent in uninfected cells and also in CD157 virus-infected cells maintained in 
medium with tet concentration of 0.01 µg/m and higher. Result was obtained by 
phosphorimaging of the bands of three western blots from three independent 
experiments and have been presented as the “mean ± SD”.  
PIU: Phosphorimager unit 
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3.3 Discussion 
Previous experience from our lab showed that stable clones expressing 
CD157 have a high tendency of losing the transgene after many passages of the 
cells (data not shown). It became a stumbling block in our studies of CD157 since 
2-3 months were needed to produce each CD157 stable clone. Hence, it is 
imperative for us to find an alternative mean of expressing CD157 in mammalian 
cells to a level that is comparable to expression in stable clones. Transgene 
expression via the adenovirus-mediated infection was an attractive option for us. 
The many advantages of using adenovirus system have previously been described 
(Kovesdi et al, 1997), including its ability to infect a wide range of cells. This 
opens up the possibilities for us to study functions of CD157 in primary cell lines 
and in animal models. The added incentive of using the Tet-Off Adeno-X 
Expression System (BD Biosciences) also gave us a possible means of control for 
CD157 expression. In this work, we have successfully established the Tet-Off 
Adeno-X Expression System in COS-7 cells. CD157 expressed using the 
constructed CD157 recombinant virus was correctly localised on the outer surface 
of cell membrane as a GPI-anchored protein. In addition, the efficiency of 
infection was very high which negates the need for us to produce stable 
transformant clones. 
Our work has shown that COS-7 cells were very susceptible to 
adenovirus infection. With an MOI of as low as 10, we were able to obtain 
optimal over-expression. This is very beneficial as too high an MOI might be 
detrimental to the cells causing cells to exhibit CPE. In adenovirus, infection of 
target cells is dependent on the Coxsackie-adenovirus receptor (CAR) for efficient 
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viral attachment (Bergelson et al, 1997). Our results predict that COS-7 cells 
express a very high level of CAR to achieve such high level of susceptibility. 
Hence, CAR expression must be taken into consideration if CD157 recombinant 
adenovirus was to be used in other cell lines. Interestingly, Hurez et al (2002), 
described adenoviral infection in lymphocytes, which were originally not 
susceptible to infection due to insufficient expression of CAR, by developing 
transgenic line which expresses human CAR. 
We have shown that the Tet-regulated control was very efficient and 
tight. When tet was absent from the culture medium, over-expression of CD157 
occurred. Tet concentration of between 0 µg/ml and 0.001 µg/ml allowed 
intermediate levels of expression while expression of CD157 was totally switched 
off at a low concentration of only 0.01 µg/ml. One possible advantage of using 
this system is that it allows for very high level of overexpression. In fact, Yin et al 
(1996) observed that the maximal gene expression level of the tet-control is higher 
than that of the wild-type CMV promoter/enhancer-driver system. Another 
advantage of the tight regulation of tet in the tet-off system is that it is not cell-
specific nor tissue-specific and its use has been widely described (Harding et al, 
1998, Mizuguchi and Hayakawa, 2001, Gu et al, 2002). However, Hop et al 
(1997) reported that though tet concentration determined the level of the transgene 
in a population of MDCK-II cells, inspection of individual cells by 
immunofluorescence demonstrated that the level of the transgene synthesis of the 
cell population was a reflection of the number of cells that produced the 
exogenous protein rather than the resultant of an identical, defined level of 
expression of each individual cell. They suggested that possibly at low tet 
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concentrations, only a small fraction of MDCK-II cells is susceptible to tet due to 
a particularly sensitive phase of the cell cycle, hence resulting in the on/off rather 
than a gradual control of expression. Our work here does not dispute nor support 
this observation. More work, such as immunofluorescence, has to be done to help 
answer the question of the mode of control of protein expression in our system. 
The observation that very low concentration of tet was used to switch off 
protein expression could also be attributed to the fact that the adenovirus 
expression system employed in this study consist of the minimal promoter and 
transactivator elements of the Tet-system incorporated into separated vectors so 
that the minimal promoter was not juxtaposed with the CMV promoter of tTA. 
This will prevent any nonspecifically induced expression (Harding et al, 1998). 
Generally, it appears that that adenovirus -mediated tet-off system is functionally 
superior to the adenoviral-mediated tet-on system due to its comparatively lower 
background transgene expression and higher induction of transgene expression 
(Mizuguchi and Hayakawa, 2001). This is especially important when the 
requirement of much higher concentrations of inducer to switch the transgene 
expression off in the tet-on system may cause a lack of inducibility in vivo due to 
an insufficient concentration of inducer (Mizuguchi and Hayakawa, 2001). 
A potential downside of the high sensitivity of the tet-regulated system 
to tet is that even small amounts of tet left in the experimental system might have 
profound effects. In this work, cells that were used for infection was grown, 
maintained and stored in a tet-free medium, using Tet system-approved FCS (BD 
Biosciences), which is a tetracycline-free serum. This is important, as previous 
studies have shown that dox, an analog of tet, bound nonspecifically to cells and 
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extracellular matrix and was slowly released after it had been removed from the 
tissue culture media (Rennel and Gerwins, 2002). The released dox could reach 
sufficiently high levels to completely suppress transgene expression (Rennel and 
Gerwins, 2002).  
The Adeno-X Tet-Off System shows great potential for future work. In 
this project, the main emphasis was on using this system for over-expression of 
proteins in transient studies. It would be of great interest if studies could be done 
to investigate the maximum length of time which the transgene can exist as an 
episomal chromosome in the infected cells. Harding et al (1998), using a similar 
system as ours, reported the persistence of the transgene for as long as 10 weeks 
after the initial infection into the rat hippocampus. Once the length of transgene 
presence was known, conditions could then be determined for the switching on of 
gene expression after it has been switched off by tet, thus giving more 
maneuverability to this system. Lastly, investigation using this system on primary 
cell cultures and animal models should be carried out since it would enable us to 
understand the functions of CD157 in an environment that is more akin to its 
natural state .The use of adenovirus thus provides a method to study the functions 
of CD157 which is complementary to that of transgenic animals. Alternatively, a 
system making use of tet-on regulation could also be established for expression of 
CD157 in animal models since a positive control might be more useful for 
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4.1 Overview 
 Earlier studies have shown that CD157 could deliver signals into cells 
and function as a receptor (Okuayama et al, 1996). The CD157-mediated p130(s) 
tyrosine phosphorylation has been reported in several cell lines including 
MCA/CD157, CHO/CD157, COS/CD157, HL-60 (Hussain and Chang, 1999), 
U937 and THP-1 (Okuayama et al, 1996). Liang et al, (2001) identified this 
protein in MCA102 cells to be focal adhesion kinase (FAK). Previously, we have 
shown that mutatant CD157 was expressed correctly in COS-7 cells via 
adenoviral mediated-infection (Section 3.1.6). In these series of experiments, we 
attempt to investigate the differences between CD157 mediated- and mCD157-
mediated-tyrosine phosphorylation (if any) and to identify the tyrosine 
phosphorylated p130 in COS-7 cells. 
 
4.2  Results 
4.2.1 Tyrosine phosphorylation mediated by CD157 and mCD157 
 COS-7 cells were infected with CD157 and mCD157 as described in 
Section 2.2.5.7. The cells were first lysed with the lysis buffer. Prior to affinity-
purification, a sample of the crude lysates was collected from each treatment to be 
analysed for β-actin which acts as the internal control. This was then followed by 
affinity-purification of tyrosine-phosphorylated proteins from the cell lysates with 
anti-phosphotyrosine agarose beads (Sigma) (Section 2.2.7), SDS-PAGE and 
immunoblotting (Section 2.2.6.2 and 2.2.6.3). The Western blots were analysed 
using an anti-phosphorylated tyrosine mAb (Transduction Laboratories). Results 
of the Western blots was shown in Figure 4.1 and a graphic representation in 



















Figure 4.1. Western blot analysis of CD157-mediated tyrosine 
phosphorylation of p130. Cells were lysed and affinity purified with anti-
phosphotyrosine agarose beads. The agarose beads were boiled with Lammeli 
loading dye for 5 mins and then the supernatant applied onto the SDS-PAGE 
followed by transblotting. The blot was then blocked for 2 hrs with 1%BSA and 
incubated with primary anti-phosphotyrosine antibodies overnight at 4oC, with 
dilution 1:1000. Subsequently, the blot was incubated with secondary antibody, 
anti-mouse IgG HRP conjugated, at a dilution of 1:2500 for 1 hr. Both primary 
and secondary antibodies were diluted with the blocking agent. Detection was 
carried using ECL (Amersham). Lane 1: Uninfected cells with serum, positive 
control, Lane 2: Uninfected cells that were serum-starved for 24 hrs, negative 
control, Lane 3: Cells were control (β-gal) virus-infected and serum-starved for 24 
hr, negative control, Lane 4: Cells were CD157 virus-infected and serum-starved 
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Figure 4.2. Upregulated p130 tyrosine phosphorylation was observed in 
uninfected cells grown with serum, and cells infected with CD157 and mCD157 
recombinant viruses that were serum-starved for 24 hrs. Cells that were uninfected 
or β-gal infected and were serum starved for 24 hrs showed much less tyrosine 
phosphorylation. In addition, it was found that if cells were maintained in a 
culture medium with serum at all times, tyrosine phosphorylation was high and 
not significantly different in all the different treatments. No further increase in 
phosphorylation could be observed in cells that expression CD157 and mCD157 
(data not shown). 
 
4.2.2 Tyrosine phosphorylation of FAK mediated by CD157 and mCD157 
 COS-7 cells were infected and treated in the same manner as for Section 
4.2.1. The Western blots were probed with six different antibodies against six 
different tyrosine residues in FAK that were known to be tyrosine phosphorylated. 
To confirm that the phosphorylated p130 is FAK in COS-7 cells over-expressing 
CD157 and mCD157, a rabbit polyclonal antibody against Tyr397 (Biosource), 
which is an autophosphorylation site for FAK, was used. Results showed that 
increased phosphorylation was observed for uninfected cells grown in culture 
medium with serum, and CD157 and mCD157 recombinant virus-infected cells 
that were serum-starved for 24hrs (Figure 4.3, Figure 4.4). This mimicked the 
results of tyrosine phosphorylation of p130 (Section 4.2.1). Similarly, cells that 
were uninfected or control (β-gal) virus-infected and serum-starved for 24 hrs 
showed much less tyrosine phosphorylation at this site too. Western blot analysis 

























Figure 4.2. Graph of CD157-mediated tyrosine phosphorylation of p130. Both 
uninfected cells and control (β-gal) virus-infected cells were serum-starved for 
24hrs and showed similar, low levels of phosphorylation of p130. There was no 
significant difference between the phosphorylation levels of these two samples. 
On the contrary, uninfected cells that were not serum-starved and CD157 and 
mCD157 virus-infected, serum-starved cells showed significantly higher 
phosphorylation levels compared to that of serum-starved, uninfected and control 
virus-infected cells. No significant difference in the levels of phosphorylation was 
found between uninfected cells that were not serum-starved and CD157 and 
mCD157 virus-infected, serum-starved cells. Experiments were done in 
triplicates. Results were obtained by phosphoimaging of the bands in the western 
blots analysed with antiphosphotyrosine antibody. Normalisation was carried out 
using β-actin. Results are presented as the “mean ± SD”. (+): cells grown in 
culture with serum, (-) cells were serum-starved for 24hrs, PIU: Phosphorimaging 
units 
 
*Phosphorylation levels significantly different from that of unifected (-) and 
control virus-infected (-) at a P < 0.05.  
**Phosphorylation levels significantly different from that of unifected (-) and 
control virus-infected (-) at both P < 0.01. 
 





























































Figure 4.3. Western blot analysis of tyrosine phosphorylation of FAK-Tyr397. 
Cells were lysed and affinity purified with anti-phosphotyrosine agarose beads. 
The agarose beads were boiled with Lammeli loading dye for 5 mins and then the 
supernatant applied onto the SDS-PAGE followed by transblotting. The blot was 
blocked overnight with 1 % BSA at 4oC. Incubation with primary anti-pFAK-
Tyr397 antibody and secondary anti-rabbit IgG HRP conjugated antibody were 
carried out at a dilution of 1:1000 and 1:2500 and for 2 hrs and 1 hr respectively. 
Both primary and secondary antibodies were diluted with the blocking agent. 
Detection was carried using ECL (Amersham). Lane 1: Uninfected cells with 
serum, positive control, Lane 2: Uninfected cells that were serum-starved for 24 
hrs, negative control, Lane 3: Cells were control (β-gal) virus-infected and serum-
starved for 24 hrs, negative control, Lane 4: Cells were CD157 virus-infected and 
serum-starved for 24 hrs, Lane 5: Cells were mCD157 virus-infected and serum-
starved for 24 hrs. 
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Figure 4.4. Graph of tyrosine phosphorylation of FAK-Tyr397. Similar to that 
of p130 tyrosine phosphorylation results, uninfected cells and serum-starved, 
control (β-gal) virus-infected cells showed low levels of phosphorylation that 
were not significantly different from each other. However, CD157 and mCD157 
virus-infected, serum-starved cells showed significantly higher FAK-Tyr397 
phosphorylation than serum-starved uninfected cells and control virus-infected 
cells, but lower than that of uninfected cells grown in medium with serum. No 
significant difference in the levels of phosphorylation was found between CD157 
and mCD157 virus-infected cells. Results were obtained by phosphoimaging of 
the bands in the western blots analysed with pFAK-Tyr397 antibody, normalised 
using β-actin. They represent the average of three independent experiments and 
have been presented as the “mean ± SD”. (+): Cells were grown in culture with 
serum, (-): Cells were serum-starved for 24hrs, PIU: Phosphorimaging units 
 
*Phosphorylation levels of uninfected cells(+) is significantly different from that 
of CD157 virus-infected(-) and mCD157 virus- infected(-) which is significantly 
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carried out with polyclonal anti-pFAK-Tyr861 antibody (Biosource) showed 
similar results to that of anti-pFAK-Tyr397 (Figure 4.5, 4.6). However, when anti-
pFAK-Tyr407, anti-pFAK-Tyr576, anti-pFAK-Tyr577 and anti-pFAK-Tyr925 
polyclonal antibodies (Biosource) were used for western blots, no significant 
differences in phosphorylation levels at their respective sites were observed for all 
the treatments (data not shown).  
 
4.3 Discussion 
 We have shown here that COS-7 cells overexpressing CD157 and 
mCD157 mediated a p130 tyrosine phosphorylation. This is in line with previous 
published results (Okuayama et al, 1996, Hussain and Chang, 1999). 
Interestingly, we found that tyrosine phosphorylation of p130 is maximal if cells 
were maintained in the presence of serum, regardless of whether CD157 or 
mCD157 was expressed (data not shown). This could possibly indicate to us that 
serum contains component(s) that is able to induce phosphorylation of p130 and 
this phosphorylation could proceed in the same manner or pathway as that of 
CD157 mediated phosphorylation. Thus, once activated, further expression of 
CD157 has not effect on it at all. To prevent any interference from the serum, all 
CD157 and mCD157 viruses infected cells were allowed to undergo a 24 hrs 
serum starvation before phosphorylation analysis. In order to address the problem 
of cell stress in serum starvation, all the negative controls were also kept in serum 
free medium for fair comparison. We also observed that the increase in p130 
phosphorylation induced by CD157 and mCD157 was not significantly different. 





























Figure 4.5. Western blot analysis of tyrosine phosphorylation of FAK-Tyr861. 
Western blotting were carried out as previously described for western blotting of 
pFAK-Tyr397 with the exception that a polyclonal pFAK-Tyr861 was used as the 
primary antibody. Lane 1: Uninfected cells with serum, positive control, Lane 2: 
Uninfected cells that were serum-starved for 24 hrs, negative control, Lane 
3:Cells were control (β-gal) virus-infected and serum-starved for 24hrs, negative 
control, Lane 4: Cells were CD157 virus-infected and serum-starved for 24hrs, 
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Figure 4.6. Graph of tyrosine phosphorylation of FAK-Tyr861. Highest FAK-
Tyr861 tyrosine phosphorylation was observed for CD157 and mCD157 virus-
infected, serum-starved cells, followed by uninfected cells grown in medium with 
serum. Serum-starved, uninfected cells and control (β-gal) virus-infected cells 
showed the lowest level of FAK-Tyr861 tyrosine phosphorylation. No significant 
difference was found between CD157 and mCD157 virus-infected, serum-starved 
cells and also between serum-starved, uninfected cells and control (β-gal) virus-
infected cells. Results were obtained by phosphoimaging of the bands in the 
western blots analysed with pFAK-Tyr861 antibody, normalised using β-actin. 
They represent the average of three independent experiments and have been 
presented as the “mean ± SD”. (+): Cells were grown in culture with serum, (-) 
Cells were serum-starved for 24hrs, PIU: Phosphorimaging units 
 
*FAK-Tyr861 phosphorylation levels of CD157 virus-infected(-) and mCD157 
virus-infected(-) is significantly different from uninfected(+) which is 
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Since the only difference in function between CD157 and mCD157 lies in their 
cyclase activity, it is very likely the cyclase activity of CD157 has no effect on its 
role as a receptor in p130 tyrosine phosphorylation. However, more work needs to 
be done before a conclusion could be made. 
 Using phospho-FAK antibodies, we have identified the p130 protein in 
COS-7 cells to be focal adhesion kinase (FAK). This protein was also identified as 
FAK in MCA102 cells (Liang et al, 2001). Focal adhesion kinase (FAK) is a 125 
kDa non-receptor tyrosine kinase implicated in signaling pathways involved in 
cell motility, proliferation and apoptosis mediated by integrins and G-protein-
coupled receptors (GPCRs) (Relou et al, 2003). The tyrosine kinase (catalytic) 
domain is located at the centre with two flanking regions, the focal adhesion 
targeting (FAT) domain at the C-terminus and 4.1/JEF domain (also known as the 
FERM domain) (Hanks et al, 2003). The FAT domain is essential for localising 
FAK to integrin adhesion sites and for adhesion-dependent tyrosine 
phosphorylation (Shen and Schaller, 1999) while the FERM domain acts as a 
negative regulator of its own activity and phosphorylation state (Cooper et al, 
2003). FAK undergoes adhesion-dependent phosphorylation on six tyrosine 
residues: 397, 407, 576, 577, 861 and 925 (Hanks et al, 2003). Tyr-397 is a major 
in vivo site of phosphorylation and the only site for autophosphorylation. It has the 
ability to interact with Src homology (SH2) domains of Src-family tyrosine 
kinases (Schaller et al, 1994). The rest of the FAK tyrosine phosphorylation 
requires a Src-family kinase for phosphorylation. Phosphorylation of FAK 
tyrosines 576 and 577 could be important for maximal FAK catalytic activity 
(Calalb et al, 1995) while phosphorylated Tyr-925 bind to SH2 domain of adaptor 
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protein Grb2 which contributes to the adhesion-induced activation of the Ras-
MAP kinase pathway. However, the functional significance of Tyr-407 and Tyr-
861 has remained uncertain (Hanks et al, 2003). 
 Our result showed that phosphorylation of FAK, at Tyr-397 and Tyr-861, 
in response to CD157 expression, is upregulated. There is a general consensus that 
Tyr-397 is a first target for FAK activation and is a pre-requisite of subsequent 
phosphorylation of other Tyr sites (Schaller et al, 1994). When CD157 was 
expressed, autophosphorylation at Tyr-397 possibly recruited the Src-family 
kinases to phosphorylate Tyr-861. Interestingly, a recent report suggested that 
phosphorylated Tyr-861 could promote FAK activation by enhancing 
intramolecular autophosphorylation of Tyr-397 (Leu and Maa, 2002). From our 
analysis using western blots with p-c-Src-Tyr216 and p-c-Src-Tyr416 antibodies, 
phosphorylation at Tyr-861 did not reflect an increase in c-Src expression or 
activation (data not shown). A possible explanation is that other members of the 
family, such as Fgr or Fyn (Schaller et al, 1994), could be responsible for the 
tyrosine phosphorylation. The downstream signal transduction mechanism as a 
consequence of CD157 dependent FAK phosphorylation at Tyr-397 and Tyr-861 
remains to be clarified.  
 Another indication that FAK might be involved in CD157 signal 
transduction is that though we did not observe the change of morphology of 
adherent cells expressing CD157 as reported by Liang et al, (2001), we did 
observe that cells infected with CD157 or mCD157 recombinant viruses were 
more weakly attached to the substrate as compared to cells that were infected with 
the control virus. 
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 Based on our results, CD157 was able to mediate FAK tyrosine 
phosphorylation in COS-7 cells even without of cross-linking with antibodies or 
ligands. A similar observation was made by Liang et al (2002) in CHO and MCA 
102 cells and they postulated that overexpression of CD157 could lead to its 
dimerisation and relocalisation to caveolae and to initiate signalling processes. 
Caveolae have been implicated as a platform for interaction among signalling 
molecules and/or with other cytoplasmic molecules which includes the src family 
kinases (Okamoto et al, 1998). Since FAK has been known to be a substrate for 
src, it is proposed that dimerised CD157 molecules are redistributed to cavaeolae 
and activates members of the src family kinases (Liang et al, 2002). 
 It would be interesting if further work could be done making use of the tet-
off control in this system to express CD157 at physiologically relevant levels. 
This would give us a better understanding of CD157-dependent signal 
transduction mechanisms under normal physiological conditions. More work 
should also be done to answer the questions of the missing linking between 
CD157 and FAK and of any possible downstream processes since it is well-
known that FAK is at a crossroad of multiple signal pathways and may play 
important roles in the assembly of signalling complexes that regulates many 
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5.1 Overview 
 In this series of experiments, we attempt to do a preliminary analysis of 
the phosphoproteome of cells over-expressing CD157 using small gel formats. 
We hope this would shed some light over ligand-independent, CD157-dependent 
signal transduction mechanisms since it is known that phosphorylation of proteins 
is a key mode of signal transduction and amplification in eukaryotic cells (Hunter, 
1995). Cell lysates were phospho-enriched, prior to 2DE and silver staining, for 
higher sensitivity of detection. Analyses were carried out on spots that were 
observed to show differential phosphorylation. 
 
5.2 Results 
5.2.1 Enrichment of Phosphoproteins 
COS-7 cells grown in T175 flasks were infected as described in Section 
2.2.5.7 with the amount of viruses and culture medium used being scaled up 
proportionately. Enrichment of phosphoproteins from the cell lysate was then 
carried out using BD Phosphoprotein Enrichment Kit (BD Biosciences) which 
allows proteins that carry a phosphate group on any amino acid to be selectively 
bound by the Phosphate Metal Affinity Chromatography (PMAC) Resin (Section 
2.2.8.1), followed by buffer exchange of the eluted sample with Tris buffer 
(Section 2.2.8.2). Generally, about 200-300 µg of phospho-enriched proteins were 
obtained from each isolation procedure. Samples from uninfected cells grown in 
serum before and after phospho-enrichment exhibited differences in their 2D 
protein profile (Figure 5.1). 5 µg of total protein of each sample was loaded onto 
each 2D gels and were silver-stained. 





















Figure 5.1. Silver-stained 2DE map of proteins from crude cell lysate and 
phospho-enriched cell lysate. 5 µg of lysate was focused on a pH 3-10 linear 
IPG strip before being separated on a 10 % polyacrylamide gel. Proteins after 
phospho-enrichment were shown to possess lower pIs and higher molecular 
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5.2.2 2DE of phospho-enriched cell lysate of uninfected cells, CD157 
virus- infected cells and β-gal virus-infected cells 
The samples were prepared as described in Section 5.2.1. 2DE was 
performed using 7 cm, pH 3-10 linear immobilised pH (IPG) strips for the first 
dimension (Section 2.2.8.2.1). Approximately 10 µg of proteins was loaded for 
each strip. After the first dimension IEF, a white band representing a very large 
amount of proteins, was present about mid-way of the IPG strips in all samples. In 
the second dimension, the strips were applied onto SDS-PAGE after two 
equilibration steps (Section 2.2.8.2.2). After silver staining (Section 2.2.8.3), 
about more than 200 spots were visualised (Figure 5.2-5.5). A vertical unstained 
streak running from the top of the gel to the bottom was seen in all gels. The 
location of this streak corresponds to the white band originally observed in the 
IPG strips.  
 Pair-wise comparisons of the 2-DE patterns were done as follows: cells 
that were CD157 virus-infected versus β-gal virus-infected and were both serum-
starved, β-gal virus-infected versus uninfected, both serum-starved and finally 
uninfected cells maintained in medium with serum versus uninfected, serum-
starved cells. We noted there were differences between all pair-wise comparisons. 
The intensity of the majority of the silver-stained spots were unchanged and these 
were then used as basis or reference points for determining differences in silver 
staining intensity of the protein spots in question. The regions that exhibited 
differences had been circled and labelled as A-K given in Figures 5.2-5.5. These 
regions are further magnified in Figures 5.6-5.8 for ease of comparison. The data 
obtained was consistently reproduced in 4 independent gels for each sample.






















Figure 5.2. Silver-stained 2DE map of phosphoproteins from CD157 
recombinant virus-infected, serum-starved cells (pH 3-10, linear IPG strip). 
10 µg of protein lysate was focused on a pH 3-10 linear IPG strip before being 
separated on a 10 % polyacrylamide gel. Black circles delineated the regions 
containing spots which showed differential expression between CD157 virus-
infected cells and β-gal virus-infected cells, both serum-starved. The results 
































Figure 5.3. Silver-stained 2DE map of phosphoproteins from β-gal virus-
infected, serum-starved cells (pH 3-10, linear IPG strip). 10 µg of protein 
lysate was focused on a pH 3-10 linear IPG strip before being separated on a 10 % 
polyacrylamide gel. Black circles delineated the regions containing spots which 
showed differential expression between CD157 virus-infected cells and β-gal 
virus-infected cells, both serum-starved. Blue circles delineated the regions 
containing spots which showed differential expression between β-gal virus-
infected and uninfected cells, both serum-starved. The results shown are 

































Figure 5.4. Silver-stained 2DE map of phosphoproteins from uninfected, 
serum-starved cells (pH 3-10, linear IPG strip). 10 µg of protein lysate was 
focused on a pH 3-10 linear IPG strip before being separated on a 10 % 
polyacrylamide gel. Blue circles delineated the regions containing spots which 
showed differential expression between β-gal virus-infected and uninfected cells, 
both serum-starved while green circles delineated the regions containing spots 
which showed differential expression between uninfected cells that were serum-
starved and supplemented with serum. The results shown are representative 2DE 
maps obtained for each treatment group. 
 

























Figure 5.5. Silver-stained 2DE map of phosphoproteins from uninfected, 
serum-supplemented cells (pH 3-10, linear IPG strip). 10 µg of protein lysate 
was focused on a pH 3-10 linear IPG strip before being separated on a 10 % 
polyacrylamide gel. Green circles delineated the regions containing spots which 
showed differential expression between uninfected cells that were serum-starved 
and supplemented with serum. The results shown are representative 2DE maps 




































Figure 5.6. Enlarged view of the differentially phosphorylated proteins 
between CD157 virus-infected and β-gal virus-infected cells, both serum 
starved. The arrows highlight the differentially phosphorylated spots. The spots 
were excised, trypsinised and analysed by MALDI-TOF-MS. 
 







































Figure 5.7. Enlarged view of the differentially phosphorylated proteins 
between β-gal virus-infected and uninfected cells, both serum-starved. The 
arrows highlight the differentially phosphorylated spots. The spots were excised, 
trypsinised and analysed by MALDI-TOF-MS. 
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Figure 5.8. Enlarged view of the differentially phosphorylated proteins 
between uninfected cells that were serum-starved and serum 
supplememented. The arrows highlight the differentially phosphorylated spots. 
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 Comparative analysis of the respective spot patterns between CD157 
virus-infected, serum-starved cells against β-gal virus-infected, serum starved-
cells revealed 11 spots that showed increased staining and 5 spots that showed 
decreased staining. Comparison of β-gal virus-infected, serum-starved cells 
against uninfected, serum-starved cells revealed 5 spots that showed increased 
staining. Finally, in the comparison between uninfected cells that were serum-
starved against uninfected cells grown in culture supplemented with serum, 2 
spots showed increased staining while 2 spots showed decreased staining. 
 
5.2.3 MALDI-TOF identification of proteins spots 
The differentially expressed spots were excised and in-gel digested with 
trypsin. Due to the low protein load, spots from all four gels were pooled. The 
identities of these proteins were established by MALDI-TOF MS analyses against 
a tryptic peptide mass fingerprint database (Figures 5.9 and 5.10). Since there is 
no database for the species Cercopithecus aethiops (African green monkey) from 
which COS-7 cells are derived from, analysis was done against all the mammals’ 
databases. The closest matched results for the two identified spots were shown in 
Table 5.1. These preliminary results must be further confirmed using other MS 
methods and/or western blotting. 
 The remaining spots on our gels remained to be identified (Table 5.2) for 
various reasons. Firstly, the protein amount present in the spots might be too low 
for a reliable analysis. For some spots, the enzymatic cleavage might not have 
been efficient or digestion did not yield enough peptides for a reliable statistical 
identification of the proteins. Others had spectra that did not allow us to identify 
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Figure 5.10. Results of databased search of tryptic peptide mass fingerprint 








A. Comparison of proteins obtained from CD157 virus-infected, serum-
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 5 Upregulated 44/7.1 
C 6 Downregulated 53/7.0 
 7 Upregulated 51/7.5 






















E 14 Upregulated 105/7.8 
 15 Downregulated 116/7.5 






















B. Comparison of proteins obtained from β-gal virus-infected, serum-starved 
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C. Comparison of proteins obtained from uninfected serum-starved cells 
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them. These proteins currently have no matches for tryptic peptide fingerprints in 
the database. Future work using other MS methods to obtain peptide sequences 
may help us to identify these proteins from the various databases. 
 
5.3 Discussion 
 In this preliminary study, we have first phospho-enriched cell lysates 
using BD Phosphoprotein Enrichment Kit prior carrying out analysis using 
2DE. The enrichment was found to be successful, since a comparison of cell 
lysates before and after phospho-enrichment showed that more proteins having 
low pIs and higher molecular weights were collected after enrichment. 
Phosphorylated proteins are expected to have low pIs and higher molecular 
weights due to the presence of the phosphate groups. In these series of 
experiments, as we had a total of four different treatments, three different sets of 
pair-wise comparisons had to be carried out. Firstly, phospho-protein profiles 
were compared between CD157 virus-infected cells and that of β-gal virus-
infected cells to detect any differences that could be due to the over-expression of 
CD157. Next, to observe whether virus infection had any effect on the 
phosphoproteomes of cells, comparison between β-gal virus-infected and 
uninfected cells, with serum starvation was made. Lastly, since results from our 
1D SDS-PAGE (Section 4.2.1) showed differences in the level of phosphorylation 
between uninfected, serum-starved and serum-supplemented cells, a similar 
comparison was made for 2DE.  
 It was observed that there were indeed differences in the regulation of 
phosphorylation of proteins between CD157 virus-infected, serum-starved cells 
 133 
 
and β-gal virus-infected, serum-starved cells. A total of 16 spots were found to be 
differentially regulated in these two samples: 12 spots were upregulated while 5 
spots were down-regulated in cells over-expressing CD157 when compared to the 
control cells, which were expressing β-gal. Our results here further support the 
view that CD157 is indeed involved in signal transduction since it has been 
widely reported that phosphorylation of proteins on serine, threonine and tyrosine 
residues on proteins is a key mode of signal transduction and amplification in 
eukaryotic cells (Mann et al, 2002). Another strong indication of CD157-
dependent signal transduction mechanisms taking place is the possible presence of 
protein isoforms observed from the 2DE profiles. Particularly of interest is that of 
spots 13 and 14, and spots 15 and 16. Both pairs of proteins have identical 
molecular weights but slightly different pI values. This could represent signalling 
proteins that have multiple phosphorylation sites. A good example of such a 
protein is FAK which has a total of six different tyrosine phosphorylation sites, 
each being phosphophorylated in response to different stimuli and leading to 
activation of different signalling pathways (Hanks et al, 2003). Previously, we 
have shown that FAK is phosphorylated on Tyr397 and Tyr861 when CD157 is 
over-expressed (Section 4.2.2). However spots 13 and 14, and 15 and 16 are 
unlikely to be FAK since they have much higher experimental pI values than that 
of FAK, which has a theoretical pI value of 6.19.  
 We have identified one of the down-regulated phosphorylated proteins in 
cells over-expressing CD157, spot 2, to be a homologue of human HSPCB 
protein. It is similar but not identical to the HSP90 and is considered to be part of 
the posttranslational modification, or protein turnover of the HSP90 family (NCBI 
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accession no: AAH07327). To date, no paper has been published for this protein 
and its function remains unclear. Heat shock proteins (HSPs) are defined as 
molecular chaperones that non-covalently bind exposed hydrophobic surfaces of 
non-native proteins. They are thought to aid cells coping with stress, and their 
expression is induced by heat, heavy metals, pH, and alcohol (Hightower, 1991). 
Major HSPs can be grouped into three size classes: 20-30, 68-73 and 80-90kDa, 
the latter commonly referred to as HSP90. HSP90 appears to interact with 
intermediately folded proteins and to prevent their aggregation (Freeman and 
Morimoto, 1996). Chaperones of the HSP90 and their co-chaperones also interact 
with a growing number of signaling molecules, including nuclear hormone 
receptors, tyrosine and serine/theonine kinases, cell cycle regulators and cell death 
regulators. However, the significance of their interaction with chaperones and co-
chaperones remains obscure (Nollen and Mormoto, 2002). HSP90 has also been 
reported to be phosphorylated at two conserved serine residues in vivo and these 
residues can be phosphorylated by casein kinase II in vitro (Lees-Miller and 
Anderson, 1989). It is interesting to note that a homologue of HSPCB protein is 
only downregulated in cells over-expressing CD157, but upregulated in β-gal 
virus-infected cells and uninfected cells. There is a possibility that its down-
regulation is related to over-expression of CD157. However, it is unclear how this 
regulation takes place and the significance of such an observation is not clear. 
Much more work needs to be done to determine whether there is any interaction 
between HSCPB proteins and CD157 and, if so, whether there is a direct 
interaction or one that is mediated through a series of other proteins. 
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 From our results, we observed that virus infections do affect the 
phosphorylation levels of cells. In our work, cells that were infected with 
adenovirus, as exemplified by cells infected with the  β-gal virus, had 5 proteins 
that had upregulated phosphorylation when compared to uninfected cells (both 
with and without serum). We have identified one of these proteins, spot e, to be a 
small heat shock protein (sHSP), a homologue of human HSP27. The sHSPs 
represent the group of HSPs having molecular weight of 16-30 kDa (Arrigo and 
Landry, 1994). In mammalian species, α-crystallin and HSP27 are the most 
abundant sHSPs. Besides, being involved in thermotolerance, the sHSPs could be 
involved in other cell functions including cell growth and differentiation as they 
have been shown to be constitutively expressed at specific stages of development 
and normal temperatures and are phosphorylated in response to a wide variety of 
stimuli including growth factors (Arrigo and Landry, 1994). It was reported that in 
MCF-7 cells, 12-O-tetradecanoylphorbo-14-acetate (TPA) treatment induced the 
phosphorylation of HSP27 and caused cell arrest (Faucher et al, 1993). HSP27 has 
also been shown to prevent apoptosis (Mehlen et al, 1996). It can act as 
chaperones binding to and stabilizing partially denatured proteins and prevent 
further denaturation and aggregation. It then delivers the partially denatured 
proteins to HSP70 or its equivalent. When ATP binds to the sHSPs, the 
conformation of the sHSP is changed and in the process, ability of sHSP to bind 
to partially denatured proteins is modified. This then allows HSP70 to remove the 
partially denatured proteins from the sHSP and renature the protein to its native 
state (Wang and Spector, 2001). Hence it is very likely that in our instance, 
adenovirus infection is presented as a stress to the cells, causing partial 
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denaturation of some proteins. The infected cells, in attempt to rectify the 
situation, expressed more sHSP to scavenge these partially denatured proteins to 
be recovered by the high molecular weight HSP. This explains why expression of 
sHSP is in fact upregulated in both CD157 virus infected and β-gal virus infected 
cells, but not in uninfected cells. In addition, it has been shown that sHSP in 
response to heat stress is phosphorylated and translocates from the cytosol to the 
nuclear compartment (Faucher et al, 1993). The same phenomenon could be 
occurring in our case as well, though the significance of this remained to be 
investigated. 
 There were a total of 4 spots showing differential protein 
phosphorylation in uninfected cells between those that were serum-starved or 
grown in serum: 2 spots were upregulated while the other 2 were downregulated. 
This was expected since we have already observed a similar result of differential 
tyrosine phosphorylation from our 1-D SDS PAGE (Section 4.2.1). It is likely that 
cells that were serum-starved were undergoing stress thus causing different 
mechanisms to be activated for protection, probably in the likes of proteins such 
as the heat shock proteins (Wang and Spector, 2001). Alternatively, there could be 
presence of undefined factors in the serum, such as growth factors or hormones, to 
elicit different signalling pathway giving rise to differential phosphorylation 
regulation in serum supplemented cells. Hence, it is of utmost importance that 
cells were maintained in the appropriate medium when studying signalling 
pathways to avoid any interference from the serum. 
 In this preliminary work, we have already shown that differential 
phosphorylation can be detected using 2DE. However, due to the limitation on the 
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amount of proteins we can load onto a 7-cm strip, we were unable to obtain 
enough proteins for all of the spots for further analysis. Hence, the next logical 
step would be to analyse these proteins using large gel formats. Recently, Ducret 
et al (2000) described a similar strategy for rapid characterisation of tyrosine-
phosphorylated proteins by mini 2DE. They first used minigel formats to rapidly 
screen large number of samples of which only the most relevant were then 
analysed by optimised, preparative large gel formats. In addition, to reduce the 
proteome complexity, they focus on just tyrosine phosphorylation since the early 
steps of signal transduction pathway mainly involved tyrosine phsophorylation. 
This could be achieved by carrying out immunodetection on 2D-blots with anti-
phosphotyrosine antibodies and then the membranes were stained with colloidal 
gold to obtain a pattern reminiscent of the silver staining of a polyacrylamide gel. 
In our context, carrying out 2D immunoblotting with either anti-phosphotyrosine 
or anti-phosphoserine/threonine antibodies could enable us to further identify the 
differentially phospho-regulated proteins as tyrosine phosphorylated or 
serine/threonine phosphorylated, giving us better insight to the signal transduction 
mechanisms of CD157. In addition, to identify the specific sites of 
phosphorylation, different mass spectrometry-based techniques could be 
employed (Mann et al, 2002). Lastly, as observed from our results, most of the 
proteins showing differential phosphorylation have pIs in the acidic range. Thus to 





















 CD 157 is a GPI anchored protein that has both a ribosyl cyclase activity 
and a hydrolase activity. Particularly of interest is that in the absence of a 
transmembrane domain, CD157 is able to transduce signals to the interior of the 
cells. In these series of experiments, we attempt to carry out adenoviral-mediated 
functional studies of CD157. 
 
6.1 Establishment of the Adeno-X Tet-Off Expression in COS-7 cells 
 We had successfully established the Adeno-X Tet-off Expression in 
COS-7 cells. Both recombinant CD157 and mCD157 were produced at high titre 
in the range of ~109 ifu/ml. These viruses, together with the regulatory Tet-off 
virus, conferred tet-regulated expression of CD157 or mCD157 when infecting 
COS-7. Overexpression of the transgene occurred with the absence of tet while 
expression is totally switched off when tet is added at a concentration of 0.01 
µg/ml. We have found this system of introducing transgene to be very efficient, 
with a percentage of about 82.4 ± 7.1 % of the total cell population expressing the 
transgene. In addition, CD157 and mCD157 thus expressed were correctly 
localised on the outer cell membrane.  
 In conclusion, this is a very efficient method of introducing CD157 and 
mCD157 into COS-7 cells, hence negating the need to produce stable 
transformant containing these inserts. 
 
6.2 CD157-mediated tyrosine phosphorylation 
 Overexpression of CD157 or mCD157 using adenovirus mediated-
infection resulted in the tyrosine phosphorylation of a p130 protein. No difference 
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in phosphorylation of p130 was observed between overexpression of CD157 or 
mCD157. Previous results from our lab have shown that a soluble form of 
mCD157 has a higher cyclase activity as compared to the wild-type CD157. 
Hence it is concluded that activation of p130 proteins is independent of the 
cyclase activity of CD157. In addition, the p130 protein was shown to be FAK 
and overexpression of CD157 or mCD157 resulted in the phosphorylation of 
Tyr397 and Tyr861 in FAK. 
 In conclusion, overexpression of CD157 or mCD157 induced ligand-
independent but CD157-mediated signal transduction mechanisms in COS-7 cells 
which are independent of the cyclase activity. 
 
6.3 Phosphoproteome analysis of cells over-expressing exogenous 
CD157 
 In this preliminary work, cell lysates were phospho-enriched and 
allowed to be analysed using small format 2DE. Differential regulation of 
phosphorylation was observed between all cell treatments. Preliminary results 
showed one of the downregulated proteins in cells overexpressing CD157 to be a 
homologue of human HSPCB while another protein, a homologue of human 
HSP27 was found to be upregulated in adenovirus-infected cells.  
 In conclusion, CD157 do induce signal transduction mechanisms when 
over-expressed. However, more work needs to done to confirm the identities of 
the two proteins identified and also the remaining of the unidentified spots using 
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